Psychiatry Flashcards

1
Q

Mental Status Examination
categories

https://www.ncbi.nlm.nih.gov/books/NBK546682/

A
  • appearance
  • behavior
  • motor activity
  • speech
  • mood
  • affect
  • thought
  • process
  • thought content
  • perceptual disturbances (delusions, illusions, Hallucionations)
  • cognition (MMSE, MoCA)
  • insight
  • judgment.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Mental Status Examination
Irregular thought processes types

A
  • circumstantial
  • tangential
  • the flight of ideas
  • loose/disorganised
  • perseveration
  • thought blocking
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mental Status Examination
Circumstantial thought process

A

describes someone whose thoughts are connected but go off-topic before returning to the original subject

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mental Status Examination
Tangential thought process

A

Is a series of connected thoughts that go off-topic but do not return to the original topic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mental Status Examination
Flight of ideas thought process

A

Flight of ideas is a type of thought process similar to a tangential one in which the thoughts go off-topic, but without completing the thought or train of thoughts; and the connection between the thoughts is less obvious and challenging for a listener to follow.

Common in MANIA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mental Status Examination
loose, disorganised thought process

A

No connection occurs between the thoughts AND no train of thought to follow.

it most often occurs in schizophrenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mental Status Examination
Perseveration

A

Perseverations are a thought process where the patient returns to the same subject, regardless of topic or question

May occur in DEMENTIA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mental Status Examination
Thought Blocking

A

observed in psychosis when a patient has interruptions in their thoughts, making it challenging to either start or finish a thought.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Mental Status Examination
Affect - definition

A

affect reflects the person’s EXTERNAL emotional expression - which can be evaluated by the interviewer. It can be described as:
- EUTHYMIC (normal, well-balanced mood)
- DYSTHYMIC (sullen, flat)
- EUPHORIC (intensely elated mood)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Mental Status Examination
Mood - Definition

A

mood reflects person’s INTERNAL emotional experience (e.g. good, ok, frustrated, angry)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Mental Status Examination
Insight - Definition

A

It refers to a patient’s understanding of their illness and functionality. Insight is typically described as poor, limited, fair, or if a previous comparison depicts worsening versus improving

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DEPRESSION Dx

A

2 core symptoms (depressed mood, low energy, anhedonia)
+
2 or more of the other symptoms
(<2 = mild; >2 + <5 moderate; >5 severe)
+
for at least 2 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

DEPRESSION Sx

A

Depressed mood (CORE) + SIGECAPS

– S = Sleep (decreased overall pattern and architecture)
– I = Interest/Enjoyment/
Anhedonia (low) (CORE)
– G = Guilt/Hopelessness/Pessimist/Self-blaming/Nihilistic
– E = Energy (low) (CORE)
– C = Concentration (decreased)
– A = Appetite (usually low, but can be increased)
– P = Psychomotor retardation
– S = Suicidal thoughts

typically, in depression, mood is worse in the morning and betters as the day progressed (this is called “diurnal variation”)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

DEPRESSION
major depression with ATYPICAL features

A
  • mood remains reactive (lifting of depressive symptoms during happy life events)
  • reversed diurnal variation (i.e. evening are the most difficult time of the day for the mood)
  • feeling rejected and unloved (interpersonal rejection sensitivity)
  • leaden paralysis (dull/heavy limbs to lift)
  • hyperphagia/weight gain
  • hypersomnia

Rx: MAOi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Dysthymic Disorder (Persistent Depressive Disorder)

A

Chronic condition characterised by depressive symptoms that:
- occur for most of the day
- more days than not
- for > 2 years

common features:
- H: Hopelessness (despondency)
- E: Energy (decreased)
- S: Self-esteem (decreased)
- S: Sleep (decreased)
- A: Appetite (decreased)
- D: decision making (impaired)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

DEPRESSION
Sleep disturbances features

A

MOST COMMON - waking up during the night and having trouble going back to sleep (also referred as middle insomnia). if successful [in going back to sleep], broken sleep thereafter

  • early morning wakening and being unable to get back to sleep at all (also referred as terminal insomnia)
  • increased REM stage
  • Decreased stage 3 non-REM stage (less stage 3 means less restorative periods => daylight tiredness)

LESS COMMON/UNCOMMON
- increased sleep latency (i.e. difficulty falling asleep) = MORE COMMON IN ANXIETY or associated with the use of nocturnal stimulants (e.g. caffeine)
- Hypersomnia and oversleeping
- Dramatic dreams (including dreams about death) ARE NOT TYPICAL OF DEPRESSION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

DEPRESSION
Risk Factors

A
  • perfectionism
  • obsessionality
  • intellectual developmental delay
  • Family history of depression.
  • Family history of Autism
  • Substance Misuse.
  • Unemployment
  • Low socioeconomic status.
  • Elderly person with cognitive decline or bereavement.
  • All family members who have experienced family violence.
    – Experience of child abuse
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

DEPRESSION
groups are at higher risk of depression

A
  • Women
  • Postpartum women
  • Young rural males
  • Adolescents
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

DEPRESSION
Features in children/adolescents

A
  • Anhedonia/Apathy may be as severe or more apparent than mood abnormalities (often expressed as severe boredom)
  • impaired concentration
  • sadness(sad appearance)
  • psychomotor agitation (“jumpy”, not relaxed)
  • despondency (hopelessness)
  • excessive irritability
  • feeling rejected, unloved, inadequacy, worhtlessness (interpersonal rejection sensitivity)
  • somatic complaints (eg, headaches, abdominal pain, insomnia), and persistent self-blame.
  • anorexia, weight loss (or failure to achieve expected weight gain)
  • sleep disruption (including nightmares)
  • suicidal ideation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

DEPRESSION
Firstline choice of treatment in children/adolescents

A

Fluoxetine

TCA’s, Mirtazapine, Venlafaxine are not recommended/approved for use in adolescents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

DEPRESSION vs SCHIZOPHRENIA

A

PATTERN

  • episodic
                                                 vs
  • progressive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

DEPRESSION
Treatment according to the classification

A
  • Mild depression: CBT > antidepressants
  • Moderate depression: CBT = antidepressants
    (initial choice of therapy based on patient preference)
  • Moderate to Severe depression: Antidepressants > CBT
    (although concurrent psychological therapies may often be helpful if the patient can concentrate enough to participate in these.)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

DEPRESSION
Antidepressants alone are ————— effective in patients with severe depression

A

50% to 60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

DEPRESSION
ECT indications

A

ECT indicated in some forms of severe depression:

  • psychotic depression
  • melancholic depression
  • voluntary patient with severe depression
  • If previous good response to ECT in patients
    with severe depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
**DEPRESSION** Inpatient treatment indications:
- depression with psychosis (ie with delusions or hallucinations); - significant risk of suicide, or homicide (eg ‘altruistic homicide’ by a woman suffering severe perinatal depression); - inadequate support at home; - seriously physically unwell ## Footnote When the patient's depression puts themselves or others at significant risk and the patient is not competent to agree to treatment, involuntary hospitalisation under the relevant mental health legislation must be considered
26
**DEPRESSION** First-line drug options
- SSRIs - SNRIs - Mirtazapine
27
**DEPRESSION** When to assess response to antidepressant
after 2 to 4 weeks of treatment
28
**DEPRESSION** % of patients with major depression that will respond to AT LEAST one antidepressant medication
80%
29
**DEPRESSION** Management if there is **PARTIAL initial response**
- increase the dose ⬇︎ - reassess in 2 to 4 weeks ⬇︎ - if no addtional response ➡︎ switch drug (first-line) - if additional response, but effect is still inadequate: ➡︎ increase the dose further if possible within the recommended dose range ➡︎ reassess in 2 to 4 weeks ➡︎ If a further dose increase is not possible, switch to a different drug (first-line)
30
**DEPRESSION** Management if there is **No initial response**
- increase the dose ⬇︎ - reassess in 2 to 4 weeks ⬇︎ - if no addtional response ➡︎ switch drug (first-line) - if partial response, but effect is still inadequate: ➡︎ increase the dose further if possible within the recommended dose range ➡︎ reassess in 2 to 4 weeks ➡︎ If a further dose increase is not possible, switch to a different drug (first-line)
31
**DEPRESSION** Antidepressant-free interval recommended when changing from one SHORT-ACTING SSRI to ANOTHER SHORT-ACTING DRUG or FLUOXETINE
Nil
32
**DEPRESSION** Antidepressant-free interval recommended when changing from FLUOXETINE to a SHORT-ACTING SSRI
1 week
33
**DEPRESSION** Full recovery after favourable response to first-line therapy
6 weeks or longer
34
**DEPRESSION** How long should treatment be for
If single episode of major depression = 6-12 months
35
**DEPRESSION** Indications for long-term prophylatic therapy
- 2 or MORE more depressive episodes within 5 years - 3 previous episodes, - single severe episode of psychotic depression - serious suicide attempt
36
**DEPRESSION** duration of long-term treatment
at least 3 to 5 years (including continuing work on vulnerability factors) ## Footnote Some patients may require lifelong antidepressant therapy.
37
**DEPRESSION** When to consider failure to respond to initial antidepressant therapy?
after **unsuccessful trials of at least two first-line treatments** (either drug or psychological)
38
**DEPRESSION** Drug options for unsuccesful trial with First-line therapy
- TCAs - MAOIs both require specialist support
39
**DEPRESSION** Discontinuation syndrome Sx
- insomnia, nausea - postural imbalance - sensory disturbances - hyperarousal - flu-like symptoms. ## Footnote SOME PATIENTS CAN EXPERIENCE THESE SYMPTOMS even after missing just 1 or 2 doses
40
**DEPRESSION** Discontinuation Syndrome duration
these symptoms are mild, last 1 to 2 weeks (usually does not require specific treatment) ## Footnote If withdrawal symptoms occur due to abrupt discontinuation, symptoms are rapidly extinguished with the reinstitution of the antidepressant
41
**DEPRESSION** Tapering regime to prevent Discontinuation syndrome
As a general rule - dose should be 1/2 every week ⬇︎ - until the daily dose is half of the lowest unit strength available ⬇︎ antidepressant can be stopped after 1 week on this dose. ## Footnote In general, antidepressants should be tapered slowly, rather than stopped abruptly, to reduce the risk of discontinuation syndrome. Antidepressant discontinuation syndrome is more likely to occur with a higher dose, a longer duration of treatment
42
**DEPRESSION** If a patient, who has successfully been stable on prophylactic dose of a particular mood stabiliser, develops acute depression, what is the next best step in management?
- **Adding an antidepressant to the prophylactic mood stabilizer**: the choices of the drug would be the same as for major depression. **SSRls first line**. - Increasing the dose of prophylactic mood stabilizer (ONLY if the patient's psychosis is indicated in coming back, otherwise continue same dose)
43
**DEPRESSION** Whcih antidepressive is considered appropiate in childhood/adolescence depression
FLUOXETINE ## Footnote **ABSOLUTE CONTRA-INDICATIONS** ARE: - TCAs = should not be used in children < 16 years. - Mirtazapine = due to its effects of sedation and weight gain, may cause problems in this age group - Venlafaxine = increased reports of hostility and suicide-related adverse effects such as suicidal ideation and self-harm.
44
**DEPRESSION** Considerations regarding pharmacological tretment in childhood/adolescence depression | Trail, change of therapy, discontinuation
- treatment trials should last: -- for 3 to 4 weeks before considering a dose increase (**as oposed to 2-4 weeks in adults**) -- and for 8 to 12 weeks before a change of therapy. - **discontinuation** trial should be considered **within 1 year **of starting treatment in children who have achieved a marked reduction in symptoms.
45
**DEPRESSION** Patient with severe depression or suicidal ideation taking HCV treatment (interferon). Management?
Stop interferon, start SSRI. (Treat depression first. Recomence interferon once the depression is managed)
46
**DEPRESSION** Drug of choice in post-cardiac depression ## Footnote https://www1.racgp.org.au/ajgp/2023/november/incidence-and-impacts-of-post-cardiac-event-mental
Sertraline ## Footnote Sertraline, citalopram, fluoxetine and mirtazapine in particular have been shown to be safe and effective for treating depression in cardiac patients. However, certain SSRIs, such as fluvoxamine, fluoxetine and paroxetine, can interact with antihypertensive medications, such as metoprolol and captopril, and should therefore be used with caution
47
Examples of Overvalued Ideas
Body dysmorphic disorder Anorexia Nervosa Hypochondriasis
48
**BIPOLAR DISORDER** Dx
**Elevated Mood + 3 of DIG FAST** or **Irritability + 4 of DIG FAST** FOR **1 week or more**
49
BIPOLAR DISORDER Sx
- D -- **DISTRACTIBILITY** - I -- **IMPULSIVITY** (please seeking behaviours) - G -- **GRANDIOSITY** (can border on the psychotic delusions and hallucinations. - F -- **FLIGHT OF IDEAS** - A -- **ACTIVITY** (psychomotor agitation/goal direct activity) - S -- **SLEEP** = decreased need - T -- **TALKATIVINESS**
50
BIPOLAR DISORDER MANIA ≠ HYPOMANIA by following features
- Minimum 7 days of symptoms (**4 days for hypomania**) - Marked functional impairment (**no functional impairment in hypomania**) - Delusions and hallucinations (psychotic features) (**absent in hypomania**) - Patient often requires hospitalisation (**less commonly required in hypomania**) - Insight and judgment are usually impaired in mania "ELEVATED MOOD IS SEEN BOTH"
51
**BIPOLAR DIORDER** Cyclothymia
≥ 2 years of fluctuating, mild hypomanic & depressive symptoms that do not meet criteria for hypomanic or major depressive episodes
52
**BIPOLAR DISORDER** Features more commonly seen in Bipolar Depression than in Unipolar Depression
- Psychomotor retardation. - Increased appetite (hyperphagia) - Increased sleep (hypersomnia) - Positive family history of bipolar disorder - Early onset of first depression before 25 years of age. - Delusions and hallucinations (psychotic features)
53
**BIPOLAR DISORDER** Suicidal Risk
- 15 x more likely to commit suicide - 25% of BD patients will attempt suicide - history of drug taking is an important finding as it can be considered as suicide attempt
54
**BIPOLAR DISORDER** MANIA vs PSYCHOTIC DISORDERS
***NATURE of delusions - grandiose - reward-oriented vs - conspiratorial thinking - paranoia - thought manipulation/control by outside force ***DISTINGUISHING SYMPTOMS - flight of ideas, distraction vs - thought disorganisation + negative sx ***PATTERN - episodic vs - progressive
55
**BIPOLAR DISORDER** Hypomania vs HISTRIONIC PERSONALITY DISORDER
Some symptoms of hypomania overlap with histrionic personality disorder. These include: - shallow emotions - flirty nature However: - flirting in hypomania = increased sexuality - flirting in histrionic personality disorder = attention seeking behaviour
56
**BIPOLAR DISORDER** treatment of acute mania
1st OLANZAPINE VO OR 1st RISPERIDONE VO OR 2 HALOPERIDOL VO OR 2 LITHIUM VO
57
**BIPOLAR DISORDER** Treatment maitenance and recurrence prophylaxis
Lithium + CBT
58
**BIPOLAR DISORDER** Duration of treatment following an acute mania episode
12 months ## Footnote If an antipsychotic is used for acute treatment, it should be withdrawn within a few months after remission
59
**BIPOLAR DISORDER** Acute mania Failure to respond to treatment
- ensure that maximum tolerable drug concentration has been achieved. - switch to a different drug (eg from a second-generation antipsychotic to lithium) - combine drugs (eg a second-generation antipsychotic + lithium) - electroconvulsive therapy (ECT)—this is a proven treatment for mania and may be extremely effective even when patients fail to respond to one or more antimanic drugs
60
**BIPOLAR DEPRESSION** Mx
1st Antidepressant (SSRI preferably) + Mood stabiliser OR 1st Quetiapine Monotherapy ## Footnote Mood-stabilising agents are SGAs (which carry the risk of metabolic syndrome. Although, for the acute resolution of symptoms agents from both classes have similar efficacy, SGAs may be slightly faster (possibly because of easier administration) and within the two classes of agents there is a slight gradient of efficacy from lithium.
61
**BIPOLAR DEPRESSION** When to cease antidepressant
preferably within 1 or 2 months of successful resolution
62
**BIPOLAR DEPRESSION** Treatment of ACUTE bipolar depression ## Footnote https://www.racgp.org.au/afp/2013/september/bipolar-disorder
QUETIAPINE ## Footnote Antidepressant monotherapy should be avoided due to the risk of inducing rapid cycling mania.
63
**BIPOLAR DEPRESSION** Failure to respond to treatment
- change to a different antidepressant or a different prophylactic drug - (ECT) —this is an effective treatment for bipolar depression and should be considered especially if the patient is psychotically depressed or displays significant psychomotorretardation or agitation
64
**Schizophrenia** DX
- 2 Sx (**(at least ONE POSITIVE sx)**) - for at least 6 months ## Footnote symptoms rarely have an acute onset. Instead, there is often a prodromal state followed by a progressive worsening of the symptoms
65
**SCHIZOPHRENIA** *Psychosis* definition
- Psychosis is a loss of contact with reality - loss of insight into the fact that one is mentally ill - Some people with psychosis have false beliefs that can best be described as **fearfulness** and **suspiciousness** (paranoia); - They may have vague fears or complaints about others controlling their lives, but many describe consistent suspicions of very specific, elaborate, and persistent plots against THEM. Very often, these beliefs are directed at family members or friends.
66
SCHIZOPHRENIA - Delusions definition
false beliefs that are inconsistent with patient's background and cannot be corrected by reasoning (result of an illness or illness process)
67
SCHIZOPHRENIA - Hallucinations definition
false perceptions in the absence of any external stimuli (e.g. auditory, visual) - no one else feels them
68
SCHIZOPHRENIA - Illusions definition
misperceptions of genuine stimuli, a specific form of sensory distortion because: - individuals have been deliberately misled (e.g. by a magician); - if their attention is diminished (e.g. delirium, fatigue, boredom or laziness) - there is a lack of visual clarity (e.g. dim lighting, semi-darkness, fog) - if they are intensely aroused by fear, passion or depression. Some people have vivid imaginations and may see faces or figures in ordinary environmental features such as clouds, tree trunks, rock formations etc. This is quite common in children and is not considered
69
**Schizophrenia** POSITIVE Sx (should not be present, but are)
'HD BS' - Hallucinations (auditory most common) - Delusions (paranoid or persecutory) - Thought Disorganisation = Behaviour (disorganised) + Speech (disorganised)
70
**Schizophrenia** features of the auditory hallucination
- comes from **OUTSIDE** of the head (as opposed to inside) - **RIGHT side** - commentary between speakers (as opposed to one voice) - mix of male and female voices - intermittent (rather than continuous) Person will find specific REDUCING BEHAVIOURS (e.g. listening to radio/watching TV/talk to others very loud, wear headphones) Person may seen reacting to what the voices are telling them ("RESPONDING TO INTERNAL STIMULI")
71
**SCHIZOPHRENIA** examples of Disorganised Behaviour
- Motor perseveration (repeating same motions over and over) - echopraxia (copying someone's movements) - **Catatonia**
72
**SCHIZOPHRENIA** Catatonia features
Stupor Mannerism Catalepsy Stereotypy Agitation Mutism Grimacing Negativism Echolalia Echopraxia | http://www.empathic-resonance.org/catalepsy-vs-cataplexy.html ## Footnote **CATALEPSY** = Rigid tone and posturing, Waxy flexibility (esistance to movement and the ability to maintain imposed positions for extended periods, as if the limbs were made of wax)
73
SCHIZOPHRENIA examples of Disorganised Speech
- clang association ( words based on its sound/ phonetics, like rhyming, rather than the actual meaning) - neologism - echolalia - perseveration (say the same word repeatedly w/o a purpose) - word salad (non-sense words) - concrete thinking (inability to think in abstract terms) - loosening association (Rapidly shifting from topic to topic, with no connection between one thought and the next) - Circumstantiality - an inability to answer a question without unnecessary and excessive detail
74
**Schizophrenia** NEGATIVE Sx ('should be present but aren't')
The 5 A's - Affect (flat/blunted) - Ambivalence/Avolition (difficulty making decisions/executing commands/poverty of thoughts) - Alogia (decreased or even absent speech) - Anhedonia - Asociality (social withdrawal) ## Footnote Although **Lack of insigh** does't fit under the P-ve or N-ve category system, it is the **most common symptom present in Schizophrenia**. More common than hallucinations, delusions, flattened affect, or ideas of reference.
75
**Schizophrenia** Most common symptom
Lack of insight ## Footnote Impaired insight is characteristic of schizophrenia. Most patients do not accept that they are ill and ascribe their experiences to the actions of other people or agencies. This usually results in lack of cooperation with doctors and nurses and an unwillingness or refusal to have treatment.**Insight is a matter of degree and involves an awareness of one's own mental condition.**
76
**Schizophrenia** EPIDEMIOLOGY/PROGNOSIS
- incidence general population 1/100 (1%) - men more affected than women 3/2 (1.5x) - earlier in men (18-25) than for in women (25-35) - men tend to exhibit more severe form and worse outcome - earlier onset - chances of recurrence after first episode (90% - similar to bipolar disorder) - SUICIDE: when it occurs, tends to happen in early stages when the insight is still preserved - negative symptoms are least likely to respond to medication.
77
Schizophrenia - RISK FACTORS
- **Monozygotic** twin **>50%** chance of developing - **Dizygotic** twin has a **15%** chance. - There is **48%** chance if **both parents** are affected - There is **12 -13%** chance if **one birth parent** is affected - There is increased risk with **advanced paternal age**, where the parent was aged **over 55** - If **second degree relative** the risk is **5-6%** - **Winter birth** - Foetal hypoxia (Pre-eclampsia and emergency c-section) - use of illicit drugs (cannabis, amphetamines, cocaine, LSD) - Urban areas - stressful life experiences/migrants - physical/sexual abuse in childhood
78
Schizophrenia - Symptoms and different age groups
YOUNG PATIENTS (15-35 yo) - spontaneous remission more common - requires higher doses - more likely to have "negative symptoms" LATE ONSET (> 40-45 yo) - less likely to remit spontaneously - respond to lower doses - persecutory delusions is most common symptom, along with accusative or abusive auditory hallucinations - less likely to have thought disorder and negative symptoms > 60 yo - less likely to remit spontaneously - visual hallucinations - less likely to have thought disorder and negative symptoms
79
**SCHIZOPHRENIA** Early signs suggestive of evolving psychosis in teenagers
- **Irritability or depressed mood** (FIRST) - **Deteriorating social or school function** -- **Withdrawal from friends and family** -- **A drop in performance at school** - **Increase in suspisciouesness** - **Hypervigilance** - **Ideas of reference and unsual rhoughts** - Trouble sleeping - Lack of motivation - Strange behavior - Sudden and bizarre changes in emotions - Severe problems in making and keeping friends - Difficulty speaking, writing, focusing or managing simple tasks.
80
SCHIZOPHRENIA timeline DDx
- Brief Psychotic disorder: > 1 day & < 1 month - Schizophreniform Disorder: > 1m & < 6 m - Schizoaffective Disorder
81
SCHIZOPHRENIA vs Schizoaffective Disorder
HATS: - H: HALF or more of the time ill must be spent with mood sx - A: psychotic sx must occur ALONE (i.e. w/o mood sx) - T: psychotic sx must occur TOGETHER (i.e during an episode of mood disorder) - S: exclude effect of SUBSTANCES or other medical conditions
82
SCHIZOPHRENIA vs BPD
- stable or improving level of disfunction after early adulthood (as opposed to progressive decline over time seen in Schizophrenia) - affect instability of BPD involves rapidly emotional shifting (as opposed to weeks to months changes) - psychotic sx tend to be an sign of distress (experienced during times os stress) - Auditory hallucinations- if present - are described as inside (as opposed to outside) and vague/unclear (as opposed to clear/vivid)
83
SCHIZOPHRENIA vs Dementia
Demented patients usually have: - - late onset - lack of prior psychiatric sx or signs - match average population in social milestones (school, work, marriage) - visual hallucinations - loss of recall of learnt information and visuospatial ability (schizophrenic patients have these intact)
84
**SCHIZOPHRENIA** Secondary causes of acute-onset psychosis in children & adolescents
* Metabolic/electrolyte disturbances * Urea cycle disorders * Acute intermittent porphyria * Wilson disease * Renal/liver failure * Hypoglycemia * Sodium/calcium/magnesium disturbances * SLE * Thyroiditis
85
Capgras syndrome
- Also called delusional misidentification syndrome - Disorder in which a person believes that an identical-looking has replaced a friend, spouse, parent, or other close family member impostor - commonly occurs in patients with paranoid schizophrenia, dementia and brain injury
86
Cotard Syndrome
patient believes they have lost important body parts, blood, internal organs, or even their soul - prevalent in schizophrenia, bipolar disorder, non-dominant temporo-parietal lesions and migraine.
87
Ekbom syndrome
Delusional infestation with parasites or worms in schizophrenic patients **≠** Willis-Ekbom disease (WED); Witmaack-Ekbom syndrome or Restless leg syndrome (RLS) is characterised by a ‘compulsive’ restlessness or need to move the legs, often associated with paraesthesiae or dysaesthesiae. Symptoms at rest or disturbing sleep, quickly but temporarily relieved by standing and walking, with nocturnal worsening of symptoms. | formication ## Footnote https://litfl.com/karl-axel-ekbom/
88
FOLIE a DEUX
 **Shared psychotic disorder** ("madness in two")  Delusion developing in a person in close relationship with another person who has an established delusion (more common in mother-daughter or sister-sister relationships)  Dominant person and submissive or dependent person in the relationship is clearly established.  Delusion similar in content.  HAPPENS IN FAMILIES – GROUPS OF PEOPLE – example is a cult. Treatment:  biggest challenge is getting the pair (or system) to accept the need for treatment.  FIRST STEP IS to separate the person or people with the secondary disorder from the person with the primary disorder, as the secondary’s delusions often don’t persist following separation.  Atypical antipsychotics aripiprazole and quetiapine most effective
89
**Schizophrenia** Delusions of Reference
Sufferers may believe that: - they are a person is special - people are noticing, watching or gossiping about them - they are being talked about on the radio - they are referred to in newspapers or television programmes - they are being followed and their movements are being constantly monitored and that what they say is recorded they do not recognise their beliefs are false. It is a form of paranoid thinking that may progress to paranoid or grandiose delusions involving complex and bizarre plots, or special powers, talents and abilities
90
**Schizophrenia** first-episode psychosis treatment
* Amisulpride OR * Aripiprazole OR * Olanzapine OR * Paliperidone OR * Quetiapine OR * Risperidone OR * Ziprasidone
91
**Schizophrenia** Interventions additional to medication to prevent relapse and improve outcome
- monitor for adverse drug effects - Shared-care programs - cognitive behavioural therapies (eg medication compliance therapy, motivational interviewing for substance abuse, coping strategies enhancement, symptom control interventions) - cognitive remediation for cognitive deficits, social skills programs, supported employment programs, accommodation and disability support options, education and training assistance, and social interventions to combat isolation - Manage comorbidities - monitor substance use - Maintain physical health and target cardiovascular risk factors - Work with family/carers - Carer assistance programs
92
**Schizophrenia** period that requires symptoms to respond to treatment
- **Agitation** = settles within **days** - **Positive symptoms** = may require **several weeks**, but some treatment response can be expected early (ie within 1 to 2 weeks of starting an antipsychotic) - Negative symptoms of schizophrenia are responsive to antipsychotics, but less so than positive symptoms
93
**Schizophrenia** How long to wait before reevaluating if prescribed medication is working in a schizophrenic patient?
**3 weeks** - Increase dose of the initial medication first, - wait until 4-6 weeks **after 4-6 weeks** 1 change to an alternate SGA, preferably (depending on positive/negative symptoms) OR 2 change to FGA: Haloperidol OR Chlorpromazine
94
**SCHIZOPHRENIA** switchover regimen for antipsychotics
**crossover phase** of at least **1 to 2 weeks**
95
**Schizophrenia** Treatment duration
- **2 years** (Following a first psychotic episode) - ONLY if there has been full remission ## Footnote Indefinite continuation of maintenance therapy is required for the majority of people with schizophrenia.
96
**Schizophrenia** drug tapering regime
- the antipsychotic can be cautiously tapered and discontinued **over a period of at least 3 months**. - monitor for early warning signs of relapse during this process and for a further 12 months after drug cessation. - If relapse occurs after cessation of maintenance therapy, longer-term treatment (ie at least 5 years) is required.
97
**Schizophrenia** Main reason for relapse
drug discontinuation due to poor concordance
98
**Schizophrenia** Risk factors for relapse
- poor insight into the purpose of medication - psychosocial stressors - substance use (alcohol, cannabis, amphetamines more common) - premature lowering of the dose - discontinuation of antipsychotic treatment
99
**Schizophrenia** Treatment Relapse Mx
- commencing a depot antipsychotic - initiation of proceedings for involuntary community treatment
100
**Schizophrenia** Treatment-resistant first step
**identify any reasons for treatment resistance:** - Is the diagnosis correct? - assess treatment concordance - Have possible underlying medical causes been identified and treated? - Is the patient reacting adversely to a current medication? - Have the drug dose and duration of administration been adequate? - assess abuse of alcohol and other drugs (eg cannabis, amphetamines) - Could an interacting drug be compromising the response? - Urine drug screening may be indicated, but this only identifies recent use and does not constitute a diagnosis of drug abuse or dependence,
101
**Schizophrenia** Treatment Resistance definition
- reasons in step one excluded PLUS - **drug trial of 6 to 12 weeks' duration** on optimal doses of **at least TWO different antipsychotics**
102
**Schizophrenia** drug of choice for treatment resistance
Clozapine
103
**Schizophrenia** Management of clozapine failure
* augmenting strategies: (no drug has demonstrated to be the best) -- amisulpride VO -- haloperidol VO -- lamotrigine VO -- omega-3 fatty acids (in particular formulations high in eicosapentaenoic acid) 2 to 3 * A trial of adjunctive ECT should be considered (However, the relapse rate is high after ceasing an acute course of ECT)
104
**Schizophrenia** Indications for the use of Clozapine
- severe and persistent positive and/or negative sx - persistent or frequently recurrent suicidal ideation and/or behaviours - severe and persistent EPS (eg tardive dyskinesia) - marked aggressive behaviour - severe comorbid substance abuse.
105
**Schizophrenia** Mx of negative symptoms (if not improved with first-line therapy)
**Change to**: 1 Amisulpride OR 1 Clozapine OR 1 a SGA other than clozapine PLUS an antidepressant (**fluoxetine** preferred) OR 2 clozapine ( PLUS an antidepressant (fluoxetine preferred) OR 2 clozapine PLUS Lamotrigine
106
Hyperactive Delirium
Patients with hyperactive delirium demonstrate features of restlessness, agitation and hyper-vigilance. They often experience hallucinations and delusions but have no insight.
107
**Behavioural emergencies** recommended methods necessary to gain control (from least invasive)
- verbal de-escalation and early negotiation (including the offer of VO medication) - ‘show of force’ (involves having a sufficient number of staff visibly backing up the clinician who is attempting to negotiate with the patient) - physical restraintv (immobilisation) - chemical restraint **NOTE**: when weapons are involved or there is a high likelihood of extreme violence), security staff and/or police will be required to disarm and restrain the patient.
108
**BEHAVIOURAL EMERGENCIES** What are the two types of treatment outcomes
-**Tranquillisation** = defined here as a state of calmness (ie not showing anxiety, anger or other emotions) -**Sedation** = defined here as a state of rousable drowsiness.
109
**BEHAVIOURAL EMERGENCIES** Oral Medication options
- **Diazepam** VO (preferred in drug withdrawal and stimulant intoxication) - **Olanzapine** VO (preferred in acute psychosis)
110
**BEHAVIOURAL EMERGENCIES** Intravenous medication option | Q.3.374
- **DIAZEPAM** IV OR - **MIDAZOLAM** IV If patient tolerant to benzodiazepine or if failure of first-line benzdiazepine USE: (in combiantion or single) - **HALOPERIDOL** IV OR - **OLANZAPINE** IV ## Footnote If combination therapy is considered appropriate, each drug should be administered separately (ie do not combine drugs in the same syringe)
111
**BEHAVIOURAL EMERGENCIES** Intravenous medication alternative
- **MIDAZOLAM** IM If patient tolerant to benzodiazepine or if failure of first-line benzdiazepine USE: (in combiantion or single) - **HALOPERIDOL** IM OR - **OLANZAPINE** IM ## Footnote Diazepam is not recommended for intramuscular injection as absorption is poor and erratic.
112
ANXIETY DISORDERS Generalised Anxiety Disorder (GAD) Dx
 Excessive anxiety/worry occurring on most days for at least **6 months** ("chronic")  Associated with 3 or more of the 6 symptoms.
113
ANXIETY DISORDERS Generalised Anxiety Disorder (GAD) Sx
"**MISERA**-ble"  M - **Muscle** tension  I - **Irritability**  S - **Sleep** (decreased)  E - **Energy** (easy fatigue)  R - **Restlessness**, feeling keyed up, on the edge  A - **Attention** (Mind going blank or difficulty concentrating) Not due to medical/ substance abuse/other psychiatric disorders.
114
**ANXIETY DISORDERS** Generalised Anxiety Disorder (GAD) Mx
 **Therapy CBT/SPS **(structured problem solving) - should always be **first-line treatment**  **If severe or CBT ineffective after 3 months, then SSRI can be introduced.** (SSRIs are decreased and ceased if patient is symptom free for 6 months)  Other options - **Buspirone** - anxiolytic - **Benzodiazepines** (short term of 2 weeks and tapered over next 2 weeks; although it has a more rapid effect it can easily lead to physical dependence and should not be used as long-term treatment) - SNRI - Beta blockers (**PROPANOLOL**) - if associated palpitation, tremors, for performance-only subtype ## Footnote Individuals with performance-only social anxiety disorder do not fear nonperformance social situations and are not socially avoidant in general. The pharmacologic treatment of performance-only social anxiety disorder includes as-needed beta blockers or benzodiazepines rather than maintenance medication. - Beta blockers (eg, propranolol) on an as-needed basis help control the associated autonomic response (eg, tremors, tachycardia, diaphoresis). - Due to their addictive potential, benzodiazepines (eg, diazepam, lorazepam) are generally avoided in patients with a personal or family history of substance use disorder. In addition, they are not preferred when performance could be impaired by sedation and cognitive side effects (eg, giving a presentation, as in this case)
115
ANXIETY DISORDERS Panic Attack Dx
- Intense *ACUTE* fear or discomfort - in which 4 or more symptoms develop abruptly - reaches a peak in 5-10 minutes (crescendo-decrescendo pattern)
116
ANXIETY DISORDERS **Panic Attack ** Sx
STUDENTS Fear C's  S - Sweating  T - Trembling - shaking  U - Unsteadiness or Dizziness/Faintness  D - Derealisation/depersonalisation/ dissociation  E - Elevated HR (Tachycardia/Palpitations)  N - Nausea  T - Tingling (Paresthesia)  S - Shortness of breath/ smothering sensation  FEAR - Fear of dying, Fear of loosing control or going crazy  C'S = Choking feeling = Chills - hot flushes = Chest pain/tightness
117
**ANXIETY DISORDERS** *Panic Disorder * Dx
1/6 people with panic attacks will develop panic disorder Panic Disorder results from anxiety about having future panic attacks that impact one's ability to lead a normal life "**SURP**-rise"  S - Sudden (without a trigger)  U - Unexpected  R - Recurrent  P - Panic attacks Rise anxiety Not associated with substance abuse
118
**ANXIETY DISORDERS** *Panic Attack/Disorder * Mx
 **FIRST**: exclude medical condition. (acute MI, asthma, thyrotoxicosis).  **At the time of attack**: - slow breathing technique (if hyperventilating) - distraction methods - benzodiazepines **Treatment to prevent further attack** - CBT (stress management, exposure and desensitisation) - avoid caffeine  if Psychotherapy is not working - **SSRI or buspirone**. - should be used in conjunction with CBT
119
**ANXIETY DISORDERS** PHOBIAS common features
- A phobia is a persistent unreasonable fear of and wish to avoid a specific object, activity or situation. - The person _recognises that the fear is irrational and is out of proportion_ to the real danger (ego-dystonic) - _ Phobias are powerful and compelling by nature_ - _They are repetitive and resistance is typically minimal and unsuccessful._ - _Although the sufferers recognise that their origin is internal from within themselves, they may feel controlled by them._ ## Footnote The fear may be of external stimuli, such as animal phobias, social phobia or agoraphobia, or internal stimuli of illness or contamination. The anxiety generated may lead to avoidance, which maintains the fear. Occasionally what begins as a specific phobia, for example 'of an animal or reptile', may generalise to a persistent dread of situations which have only a tenuous link with the original stimulus.
120
**ANXIETY DISORDERS** Agoraphobia
It is generally a specific coping mechanism that arises in response to : - fear of crowds, getting trapped and not having an escae alternative. - it can occur in **panic attacks/disorder where one begins to avoid going out at all preferring to stay in the safety of their own home** (become housebound) where they feel less vulnerable to panic attacks ## Footnote It is generally a specific coping mechanism that arises in response to having **panic attacks/disorder where one begins to avoid going out at all preferring to stay in the safety of their own home** (become housebound) where they feel less vulnerable to panic attacks. it develops in about 1/4 of people with Panic Disorder (it is a marker of severe Panic Disorder
121
**ANXIETY DISORDERS** Social Phobia/ Social Anxiety Disorder
Persistent fear of **interpersonal rejection** Affected individuals avoid social or performance situations in fear they'll embarrass themselves or be judged as anxious or stupid
122
**ANXIETY DISORDERS** PHOBIAS Mx
The treatment of choice in phobic disorders is **CBT + EXPOSURE THERAPY** (anxiety-management skills + systematic desensitisation). Benzodiazepines have little or no place in the routine management of phobias and their usage may delay or impede efforts to master symptoms using behavioural techniques. ## Footnote his involves the graduated exposure of the person to the feared stimulus or situation while practising relaxation and controlled breathing until the level of anxiety experienced is manageable or has dissipated. This is systematic desensitisation.
123
**ANXIETY DISORDERS** Disorders that often present with anxiety as chief complaint and their differences
- OCD (obsessional thoughts) - Somatisation ( anxiety to physical sx) - PTSD (re-experiencing trauma)
124
**ANXIETY DISORDERS** Medical conditions that often present as anxiety
 Pheochromocytoma (rare)  Diabetes Mellitus (**Hypoglycaemia** is the **commonest** **underlying organic cause** of **anxiety symptom**s)  Arrhythmias (Paroxysmal supraventricular tachycardias)  Temporal epilepsy  Hyperthyroidism  Alcohol withdrawal  Drug intoxication or withdrawal **NOTE:** Carcinoid does not cause anxiety. Carcinoma of the bronchus and hyperparathyroidism are more likely to present with depression.
125
**OCD** Definition of Compulsion
Compulsive behaviours are: - **repetitive actions driven by anxiety or distress** (purposeless); - They often serve as a coping mechanism to alleviate stress or prevent a feared event or situation through a repeated behaviour - Associated with negative reinforcer (taking something - ie anxiety - away) ≠ Impulsive behaviour are: - spontaneous actions performed without forethought or consideration of the consequences - These behaviours are **driven by immediate desires** - Associated with positive reinforcer ( often meaning is pleasurable)
126
**OCD** Are patients egosyntonic or ego-dystonic with how they view their disorder?
**Ego-dystonic** = recognise one's intrusive thoughts are not reflective (**discordant**) of their true desires (**insight is preserved**)
127
OCD Clinical features
- **obsessive thoughts and compulsive rituals** - Compulsions are "repetitive purposeful", "intentional" behaviours conducted to prevent an adverse outcome - While OBSESSIONS are REQUIRED for the diagnosis, COMPULSIONS are OPTIONAL (not everyone with obsessions will develop compulsions; however, everyone with compulsions will have obsessions) ## Footnote - Obsessions: Recurrent, intrusive, anxiety-provoking thoughts, urges, or images - Compulsions Response to obsessions with repeated behaviors or mental acts. Behaviors not connected realistically with preventing feared event
128
**OCD** Obsessive thoughts characteristics
"**I MURDER**"  I - Intrusive  M - Mind-based (not thought insertion)  U - Unwanted  R - Resistant  D - Distressing  E - Ego-dystonic  R - Recurrent ## Footnote * Time-consuming (>1 hr/day) or causing significant distress or impairment
129
**OCD** Epidemiology
- Men and women are "EQUALY" affected - once of symptoms often during childhood or young adulthood (< age of 20-30)
130
**OCD** Mx
**optimal management always include a combination** of both: CBT **(ERP = exposure & response prevention) ** + SSRI NOTE: Alcohol makes OCD symptoms feel better for a while, however, it is not recommended as a therapy due to the risk of alcohol abuse NOTE: "**CLOMIPRAMINE**" is a TCA and can be used as a second-line alternative if CBT+SSRI have failed or in more severe cases of OCD NOTE Neurosurgery (i.e cynguloctomy) is reserver for severe/refractory cases ## Footnote SINGLE THERAPY IS NOT EFFECTIVE IN CBT - combination therapy is always the first line treatment Exposure treatments are aimed at confronting patients with what is feared (and is causinganxiety), while encouraging them to block any behaviours which may prevent or terminate the exposure (response prevention). A review of their fears is encouraged, so that patients realise that the catastrophic or terrible consequences which they fear, do not occur.
131
Risks of developing Obsessive Compulsive Disorder
- Anxiety - Depression - Alcohol or substance misuse - Eating disorders - Body dysmorphic disorders - Chronic physical health problems (skin problems due to excessive hand washing)
132
**BODY DYSMORPHIC DISORDER** Key features
"**FIX ME DOC**"  FIX - Fixation on perceived flaw  M - Medical care-seeking  E - **Ego-Syntonic**  D - Disabling  O - Obsessive thoughts  C - Compulsive behaviours
133
**BODY DYSMORPHIC DISORDER** patients are ego-syntonic or ego-dystonic with how they view their disorder?
Ego-syntonic Patient does not admit that their fears and preoccupations are extreme or excessive
134
BODY DYSMORPHIC DISORDER Mx
CBT ± SSRI
135
Comorbid conditions found with BDD
- Anxiety - Social Phobia - OCD - Delusional disorder - Alcohol or substance misuse
136
**GENDER DYPHORIA (GD)** Clinical features
* Experiences persistent (>6 months) incongruence between assigned & felt gender * Desires to be another gender * Dislikes own anatomy, desires sexual traits of another gender * discomfort with the development of unwanted secondary sexual characteristics. * Believes feelings/reactions are of another gender * Feels significant distress/impairment
137
**GENDER DYPHORIA (GD)** Management
* Assessment of safety * Support; psychotherapy (individual, family) * Referral to specialist Gender identity-affirming care services (medical & mental health multidisciplinary)
138
**HYPOCHONDRIASIS** Dx or Illness Anxiety Disorder
fears and symptoms persist for ≥ 6 months
139
HYPOCHONDRIASIS features
- Hy**p**ocondriasis = **P**reoccupation with or **fear of having** (as opposed to getting) **a serious disease**, despite medical reassurance, leading to significant distress/impairment. - often present with a (self)-diagnosis - Ego-syntonic (involuntary/non-volitional & unconsciously) - Often involves history of prior physical disease.
140
HYPOCHONDRIASIS Mx
- group therapy ± SSRI - schedule regular appointments with the patient’s primary caregiver (if existing)
141
Difference between Hypochondriasis & Somatisation
Hypochondriasis: patient presents with a diagnosis focus on the disease, not a particular symptom **failure to respond to reassurance** Somatisation: - presents with a variety of unexplained sx - primary focus of preoccupation/concern with the symptoms themselves
142
**HOARDING DISORDER** Management
CBT and SSRI ## Footnote nonetheless, patient usually don't respond well
143
**HOARDING DISORDER** Define *Diogenes syndrome*
- squalor and decline in personal hygiene - sometimes hoarding useless items - significant frontal lobe impairment
144
**PTSD** Signs & Symptoms
"**TRAUMA**"  T - Trauma **core**  R - Re-experiencing **core**  A - Arousal **core**  U - Unable to function  M - Month ( present > 4 weeks)  A - Avoidance **core**
145
PTSD Trauma features
Must be: - life-threatening - actual or threatened physical and/or sexual violence - secondary exposure to a traumatic event (such as about a spouse or family member) also qualifies NOTE: other non-life-threatening events such as **harassment** and **non-violent bullying** do **not "qualify" as trauma per DSM-5** (despite these being distressing and resulting in S/S indistinguishable from PTSD) and ADJUSTMENT DISORDER with ANXIOUS MOOD should be considered
146
**PTSD** Arousal phenomenon
Persistent (chronic) and generalised - Hyper-arousal State: increased anxiety and awareness - hyper-vigilance: constant scanning of their environment for clues to the presence of danger - MISERA-ble = MUSCLE tension, IRRITABILITY, trouble with SLEEP, low ENERGY, RESTLESSNESS, inability to pay ATTENTION (poor concentration and memory) to non-trauma related stimuli
147
**PTSD** Duration
**Symptoms must be present for at least 1 month** **NOTE**: it does not necessarily mean that symptoms have to present in the first month after the trauma occurs (delayed onset is more characteristic) **ACUTE**: symptoms last < 3 months **CHRONIC**: symptoms last > 3 months **DELAYED ONSET**: Sx appear at least 6 months after traumatic event
148
**PTSD ** vs **ACUTE STRESS DISORDER**
When the core trauma-related symptoms have **not yet reached ONE month in length** NOTE: the presence of ASD immediately following a traumatic event does not rule in later development of PTSD, nor does its absence rule it out ## Footnote NOTE: the presence of ASD immediately following a traumatic event does not rule in later development of PTSD, nor does its absence rule it out
149
**PTSD** Avoidance features
– physical avoidance (people, places, things) – Psychological avoidance (emotional numbing) an attempt to self-protect against strong negative emotions; however, interferes with ability to experience positive emotions such as joy (flattening affect), satisfaction, love (detachment from others)
150
**PTSD** Risk factors
- alcohol and drug abuse - previous history of depression - previous history of sexual abuse. - Victims of domestic violence
151
PTSD Features that predict a higher chance of having PTSD one year from the incident
- the intentional nature of the trauma (eg sexual abuse/rape/assassination attempt) - Experiencing the trauma alone - lack of social support network - presence of at least one pre-trauma psychiatric diagnosis NOTE: Onset of symptoms soon after the traumatic event (ie ACUTE DISTRESS DISORDER)
152
PTSD Mx
- CBT (***FIRST-LINE TREATMENT***) * trauma-based psychotherapy, crisis intervention therapy, * EMDR (eye movement desensitisation and reprocessing therapy) - Life-style modifications (sleep hygiene, relaxation techniques) **NEXT STEP** - If not responding, then **SSRI** (it does not help specifically with either sleep or nightmares)
153
**PTDS** Initial response to an *acutely traumatised state*
- provide a comforting and consoling presence - to listen empathically Most people following traumatic events recover spontaneously without specific psychological interventions **NOTE:** **the current consensus is that debriefing is not clinically indicated as an immediate intervention and may even be harmful**.
154
ADJUSTMENT DISORDER with ANXIOUS MOOD or DEPRESSIVE MOOD features:
Diagnostic criteria: onset of **anxiety/depression symptoms within 3 months of identifiable psychosocial stressor**(s) which: - are time-limited (Once the stressor or its consequences have terminated, the symptoms do not persist for more than 6 months) - Aren't severe enough to meet criteria for MDD or GAD and incurs in response to as stress that isn't life-threatening or violent enough to be trauma - are in excess of normal expectations of reaction to the stressor(s) - are not due to another identifiable mental disorder - are not part of a continuing pattern of overreaction to stress impair social or occupational functioning. - Significant impairment in social, occupational, or other important areas of functioning
155
**ADJUSTMENT DISORDERS** Mx
- primary interventions = psychological supportive therapy including counselling, relaxation, problem solving, stress management, and (CBT) - **short-term pharmacotherapy** (**usually < 2 wks**) with **BZ** = if the symptoms are severe, if significant impairment of functioning and there is inadequate response to psychological interventions. **NOTE: Most drugs used to treat anxiety (ie [SSRIs]) take a number of weeks to produce an effect, thus in this situation the use of a BZP may be appropriate** ## Footnote NOTE: Intermittent use, on occasional days when there is a severe exacerbation of anxiety, may suffice and is preferable to continuous treatment.
156
**ADDICTION/SUBSTANCE ABUSE** overall pattern
- Repeated use - Reinforcers (Positive) - Repercussions (Njuegative)
157
**ADDICTION/SUBSTANCE ABUSE** vs OCD
**Compulsive** vs. **Impulsive**: The primary difference between compulsive and impulsive behaviours lies in their motivation and execution. - **Compulsive** behaviours stem from an internal drive to alleviate the fear and anxiety triggered by obsessive thoughts - **Impulsive** behaviours are spontaneous and often driven by desires.
158
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' The stages of intervention
the **5A**s framework — **ask** (about smoking) — **assess** (motivation & nicotine dependence) — **advise** (to quit) — **assist** (with cessation) — **arrange** follow-up
159
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' Nicotine dependence levels
— high dependence — moderate dependence — low-to-moderate dependence — low dependency
160
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' Nicotine HIGH Dependence
waking at night to smoke or smoking within the first 5 minutes after waking = usually smokes > 30 cigarettes daily
161
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' Nicotine MODERATE Dependence levels
smoking within 30 minutes after waking = usually smokes 20- 30 cigarettes daily
162
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' Nicotine LOW-TO- MODERATE Dependence levels
not needing to smoke within the first 30 minutes after waking usually smokes 10-20 cigarettes daily
163
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' Nicotine LOW Dependence levels
not needing to smoke in the 1st hour after waking usually smokes < 10 cigarettes daily.
164
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' When to intervene for stopping smoking with pharmacotherapy
Recommended for: - **moderately to highly** nicotine-dependent smokers **&** - who **express an interest** in quitting
165
**ADDICTION/SUBSTANCE ABUSE** "*Tobacco*' Interventions for smoking cessation
Best results are usually achieved when **pharmacotherapy is combined with counselling and support**
166
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' Smoking cessation First-line pharmacotherapy options
- Nicotine Replacement Therapy (NRT) - Varenicline - Bupropion
167
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' NRT indications/suitability
– Combination NRT (ie patch and oral form) preferred (*Combination NRT is as effective as varenicline and more effective than single types of NRT.) - can be used by people with **cardiovascular disease** (Caution is advised for people in hospital for acute cardiovascular events, but NRT can be used under medical supervision if the alternative is active smoking.) - NRT may be considered in women who are pregnant if they were unsuccessful in stopping smoking without pharmacotherapy. If NRT is used, the benefits and risks should be explained carefully to the patient by a suitably qualified health professional. The clinician supervising the pregnancy should also be consulted. - NRT (ie patch, intermittent) is considered an **option** for **breastfeeding mothers**. Infant exposure to nicotine can be reduced further by taking intermittent NRT immediately after breastfeeding. - cannot be used in children aged < 12 years
168
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' Varenicline indications/suitability
- The **most effective single-form** pharmacotherapy for smoking cessation - **not recommended for pregnant and breastfeeding** women, nor for **adolescents.** - causes nausea in 30% of patients - **requires caution in CKD patients**
169
**ADDICTION/SUBSTANCE ABUSE** '*Tobacco*' Bupropion indication/suitability
* less effective than varenicline for smoking cessation. * **contraindicated in patients with a history of seizures, eating disorders and those taking monoamine oxidase inhibitors** * **not recommended** for women who are **pregnant or breastfeeding** * Should be used with caution in people taking medications that can lower seizure threshold (eg antidepressants, antimalarials, oral hypoglycaemic agents)
170
**ADDICTION/SUBSTANCE ABUSE** "*Alcohol Use Disorder*" CAGE questionnaire in Alcohol Use Disorder (AUD):
"YES" to 2 or more is a POSITIVE screen:  C - **CUT** Have you ever felt you should Cut down on your drinking?  A - **ANNOYED** Have people Annoyed you by criticising your drinking?  G - **GUILTY** Have you ever felt bad or Guilty about your drinking?  E - Have you ever had a drink first thing in the morning to steady your nerves or to get rid of a hangover? (**Eye-opener**)
171
**ADDICTION/SUBSTANCE ABUSE** "*Alcohol Use Disorder*" Overdose/Intoxication Mx
Treatment of intoxication and overdose is **supportive** and **symptomatic**, with careful monitoring of: - BAC - airway - level of consciousness and responsiveness - oxygen saturation - hypoglycaemia and metabolic acidosis - Alcoholic Hallucinations Stimulants should not be given.
172
**ADDICTION/SUBSTANCE ABUSE** "*Alcohol Use Disorder*" "**ACUTE** *Alcohol withdrawal syndrome*"
Symptoms usually appear within **6-24 hours** of the last consumption of alcohol (BAC ≤ 0.1%). can last up to **72 hours** The signs and symptoms may be grouped into three major classes: autonomic, gastrointestinal, and CNS changes that represent manifestations of sympathetic hyperactivity. AUTONOMIC: - Sweating - Fever - Tachycardia - Hypertension - Tremor GASTROINTESTINAL: - nausea and vomiting - Dyspepsia - Anorexia CNS - Anxiety - agitation - **Delusions/Hallucinations** - Insomnia and vivid dreams - **Seizures** (occasionally - 5% - observed, grand mal type = generalised, not focal) LAB - **↑ GGT** - **↑ AST/ALT RATIO** ## Footnote Seizures is the hallmark feature of Acute Alcohol Withdrawal (in contrast to Delirium Tremens which normally does not present with seizures) and the most concerning intercurrence
173
**ADDICTION/SUBSTANCE ABUSE** "**Acute** Alcohol withdrawal" Mx
- Diazepam VO -- Oxazepam VO (if liver disease) - Thiamine (IM or IV) - AVOID antipsychotics (which lower seizure threshold). If hallucinations are not responding to Benzodiazepines alone, add: - Olanzapine VO other meaures include: - Nursing in well-lit and quiet environment - Monitoring for and treating hypoglycaemia - Rehydration - High calorie high carbohydrate diet,
174
**ADDICTION/SUBSTANCE ABUSE** Alcoholic Hallucinosis vs DTs
Alcoholic Hallucinosis * **develop 6 - 24 hours of the last drink** * typically persist for up to 72 hours * transient **auditory hallucinations** * Usually benign * **Associated with Alcohol intoxication** DTs * **occurs 24-72 hours after stopping/significantly reducing alcohol consumption** * Autonomic instability (↑ BP, ↑ HR) * **Usual course is 3 days, but persist for up to 14 days** * **Associated with withdrawal**
175
**ADDICTION/SUBSTANCE ABUSE** "*Delirium Tremens (DTs)*" Ddx
Delirium tremens is a diagnosis by exclusion, so before commencing treatment, screen for other factors contributing to delirium, in particular: - subdural haematoma - head injury - Wernicke’s encephalopathy - hepatic encephalopathy - hypoxia - sepsis - metabolic disturbances - intoxication with or withdrawal from other drugs
176
**ADDICTION/SUBSTANCE ABUSE** Benzodiazepines use & intercurrent illness
* IV Diazepam should be avoided if possible. -- Onset of action isn't much faster than with VO -- there is a greater likelihood of causing severe adverse effects such as respiratory depression. -- If an injection is necessary, it must not be diluted and it must be given slowly over several minutes to minimise the risk of respiratory depression or arrest. Close cardiorespiratory monitoring is essential. * If Severe liver disease -- Oxazepam VO * Severe chronic airflow limitation Use benzodiazepines with caution and with close monitoring. -- Midazolam IV or -- Short acting Benzodiazepine = Temazepam or Oxazepam
177
ADDICTION/SUBSTANCE ABUSE Thiamine
- Initial dosing is with IV or IM thiamine (absorption of oral thiamine is slow and may be incomplete in patients with poor nutritional status) - Administer thiamine before giving any form of glucose when possible. A carbohydrate load in the presence of thiamine deficiency risks precipitating Wernicke’s encephalopathy.
178
ADDICTION/SUBSTANCE ABUSE Long-term management of alcohol dependence
- acamprosate - naltrexone - disulfiram + best used in conjunction with psychosocial therapy For each of these drugs, treatment duration of **6 months** or more is recommended.
179
ADDICTION/SUBSTANCE ABUSE AUD - Acamprosate
* started following cessation of the acute phase of alcohol withdrawal, ie approximately 1 week after cessation of drinking * Treatment should continue even if the patient lapses; INDICATIONS - moderate to severe AUD - Does not interact with alcohol - compliance may be challenging due to dosing regimen CONTRAINDICATIONS - hypersensitivity to the drug - renal insufficiency - severe hepatic failure - Tetracyclines may be rendered inactive by the calcium component in acamprosate. ## Footnote * **Modulates** GABA/glutamate
180
ADDICTION/SUBSTANCE ABUSE AUD - Naltrexone
INDICATIONS - moderate to severe AUD CONTRAINDICATIONS - acute hepatitis or severe liver failure. - There are no well controlled studies of the safety of naltrexone during pregnancy or lactation. - not suitable for people who are opioid dependent or who have pain disorders/ require opioid analgesia ## Footnote * **blocks** the effect of endogenous opioids released following alcohol intake
181
ADDICTION/SUBSTANCE ABUSE AUD - Disulfiram
* most effective with supervised administration * Careful monitoring of cardiac and liver condition is recommended if disulfiram treatment is started. Liver tests should be performed fortnightly for 2-3 months, particularly in those with abnormal tests at baseline. INDICATIONS - appropriate for patients who are motivated to ***ABSTAIN*** from alcohol. It should not be prescribed for patients who have a goal of reduced alcohol intake. - It is beneficial for patients that accept a need for an external control on their drinking and are prepared to be supervised in the daily dosing of the medication. CONTRAINDICATIONS - cardiovascular, hepatic or pulmonary disease - Safe use of disulfiram during pregnancy or lactation has not been established - Patient has not consumed alcohol in the previous 24 hours ## Footnote * primarily works by inhibiting the action of aldehyde dehydrogenase - enzyme involved in the second step in the metabolism of alcohol, that converts acetaldehyde to acetate. This leads to the accumulation of acetaldehyde following consumption of alcohol while on disulfiram. The resulting symptoms are unpleasant
182
**Pyromania** Features
- impulse control disorder (an impulse to set fires and involves deliberate and purposeful fire setting with anxiety prior to the act and gratification or relief following the act of setting the fire) - They do not do it to seek public attention. - They do not like to play with fire - The fire is not set for monetary gain out of any sense of revenge or anger (which is arsoning)
183
**ADHD ** Inattention signs:
"**DETaILS OFF**"  D - Details are sloppy  E - Easily distracted  T/A - Task Avoidance  I - Ignores instructions  L - Loses things  S - Sustained attention (poor)  O - Organisation (poor)  F - Forgetful  F - Fails to finish tasks
184
**ADHD** Hyperactivity signs:
"**HE RILED UP**"  H - Hiperactive  E - Energetic  R - Running around  I - Interrups/Impulsivity  L - Loud  E - Effusive  D - Delay Intolerance  U - Unseated  P - Prematurely answers questions
185
**ADHD** Dx:
- Does not require symptoms of both domains (Inattention or Hyperactivity) to co-exist - It's a diagnosis of exclusion - ADHD = Inattention and hyperactivity that is excessive, unrelated to other disorders and has been observed in **multiple** settings from a young age (**in case of divorced parents, it is important to obtain colateral history from the other parent that is not present on the first assessment**) - symptoms are chronic (as opposed to episodic and fluctuating) - must be present for at least **6 monyhs** - symptoms must've been present before age of 7 y "**FIDGETY**"  F - Functionally impairing  I - Inattention  D - Disinhibition  G - Greater than normal  E - Exclude other disorders  T - TWO or more settings  Y - young age (12 or less) ## Footnote - **ADHD does not present with failure to achieve developmental milestones** - **ADHD can maintain the ability to focus on activities they find intrinsically interesting or enjoyable**
186
**ADHD** Tools to assist on the diagnosis
- Behavioral Rating Scale - Visual & Hearing Assessments - Classroom Observation - Psychometric Assessment ## Footnote Behavioural rating scales give an objective **measure of the symptoms** across various domains and can assist in determining if symptom criteria for ADHD have been met. It is recommended that they be obtained from home and school at least. However they are **not diagnostic**. **The person completing the scales should have known the subject person for at least a month**. Psychometric assessment can exclude **intellectual impairment **and learning disorders. ADHD has a high rate of comorbidity with learning disorders, so there will need to be a review of the child's academic competency.
187
ADHD Risk factors
- Male: Female 2:1 - Family history of ADHD - in utero tobacco exposure - maternal stress - premature delivery - low birth weight - poverty
188
ADHD Prognosis
- Predominant inattentive subtype is more common ( ~ 2/3) - Combined subtype 20% - Predominant hyperactive subtype 10% - Hyperactive subtype often prominent during school and decreases with age - Inattentive subtype persists at same level throughout life ## Footnote ***60% will continue to exhibit symptoms into adulthood***
189
**ADHD** Adult main features
Symptoms are more subtle, and are subject to change: - Hyperactivity may be replaced with restlessness - impulsivity may be replaced with inability to control emotions or social inappropriateness.
190
**ADHD** Treatment
* CBT (behavioural management and training) + family therapy +/- * Pharmachological - 1st line: Stimulants (**methylphenidate, dexamphetamine**) - 2nd line: **Atomoxetine** | drugs alone may not have a longer-term benefit on academic performance ## Footnote The alternative stimulant should be considered if the maximum dose of the first drug is reached and there is no significant improvement - after ** ONE month ** of treatment or - if there are major adverse effects. **With rare exceptions, do not use stimulants in children aged younger than 4 years**
191
Mechanism of action of **ADHD** medication
- STIMULANTS: Inhibition of dopamine and norepinephrine reuptake - ATOMOXETINE: Selective Noradrenaline reuptake inhibitor
192
**ADHD** Stimulants side-effects and Mx
- headache - abdominal discomfort *However, many children become tolerant to these effects without the need to reduce doses.* - Increased sleep latency - appetite suppression are common. *Due to the anorectic properties of these drugs, doses should be given at or after breakfast and lunch* - growth restriction (relatively minor) *The weight and height of children should be monitored routinely during their treatment. When there is concern about a child's growth, drug holidays may be appropriate at times when some increase in symptoms may be acceptable (eg weekends and school holidays)* - Social withdrawal and tearfulness *may be indicators of an excessive dose.*
193
**ADHD** Contra-indication/precautions
- should be used with caution in children with: * structural cardiac abnormalities, serious heart problems or those with conditions that may be exacerbated by increased pulse rate or BP * family history of sudden death, syncope ---->>> An assessment by a cardiologist is suggested. ---->>> Promptly evaluate children who develop exertional chest pain, unexplained syncope or other cardiovascular symptoms. - Avoid stimulants in children with a history of psychosis as a psychosis may be precipitated.
194
**ADHD** Comorbid mental disorders
- oppositional defiant disorder - conduct disorder - learning and language problems - autism - GAD - OCD
195
**ADHD** DDx that can mimic
"**PAN LID NOISE**"  PAN - Parenting, Abuse, and Neglect  LID - Learning, Intellectual, and Developmental Disabilities (these conditions do not respond to the treatment for ADHD; in addition, they present with failure to reach milestones  N - Nutrition  O - Other conditions (DM, Seizures, MDD, ODD, CD)  I - Intoxication  S - Sleep  E - Environment
196
**ADHD** vs ODD/CD
- ADH has no intention to misbihave or be disruptive - ADH have remorse if they realise they've upset others - ADH disruptive behaviours rarely escalate to the level of fraglant disregard to rules and others rights like in CD
197
**AUTISM SPECTRUM DISORDER (ASD)** core symptoms
- deficitis in social communication (Austistic **A**loness) - restrictive and repetitive interests & activities (Insistence upon **S**ameness) ## Footnote Two domains
198
**AUTISM SPECTRUM DISORDER (ASD)** Dx
both core symptoms social communication & Restricted interests and behaviours + **D**evelopmental (1-3 years old) onset ## Footnote "the criteria for diagnosing is in the name of the disorder: "**ASD**"
199
**AUTISM SPECTRUM DISORDER (ASD)** Signs/Symptoms deficits *social communication* domain
- speech delays/Lack of speech - difficult understanding and using non-verbal communication - Overly literal - indifference to the presence of others - Reciptocity (absent) - Turn-taking (absent) - Sharing (absent) ## Footnote ASD is most strongly associated with delays in speech-related milestones rather than motor milestones. These deficits often do not begin until the age of 1 at the earliest.
200
**AUTISM SPECTRUM DISORDER (ASD)** Signs/Symptoms Restricted interests and activities domain
- paticular fixations and fascinations - stereotyped or repetitive movements or posturing of body, arms, hands or fingers
201
**AUTISM SPECTRUM DISORDER (ASD)** Other sings and symptoms
although common (occurring in 60-80% of cases), they are not required for a diagnosis - disturbance in sensory perception * hypersensitivity* = aversion to sounds or textures * hypopsensistivity* = high tolerance to pain or temperature - motor sings * poor coordination * low muscle tone * unusual gait
202
ASD vs ADHD
- patterns must be observed in multiple settings from early childhood FOR BOTH conditions - **ONLY ASD** is associated with **milestone delays**
203
**AUTISM SPECTRUM DISORDER (ASD)** Mx
- beihavioural training = teach specific adaptive skills - speech language therapy = teaching skills to overcome communication deficits ## Footnote medications play no role in improving outcomes in autism
204
**ASD** Risk Factors
- family history (1st degree relative) - childreen of older fathers - M>F (4x)
205
**ASD** and other causes for speech delays
"APHASIC"  A - Autism  P - Physical deficits  H - Heating impairment  A - Abuse/neglect  S - Selective Mutism  I - Intelctual Disability  C - Cerebral Palsy ## Footnote For many patients, speech delay is the initial reason for a formal evaluation of autism. Hence, other causes of speech delay must be ruled out
206
**PERSONALITY DISORDERS** Five personality traits
"**OCEAN**"  O - **Openness** to experience  C - **Conscientiousness** (tendency to act in accordance with both personal and societal expectantions)  E - **Extroversion** (tendency to engage with the external environment/other people)  A - **Agreeableness** ( priority that one places on getting along with other people)  N - **Neuroticism** (tendency to experience negative emotions over positive ones)
207
**PERSONALITY DISORDERS** DDx
The dysfunction seen in personality disorders is **chronic** and **enduring** - rather than *transient* and *episodic* the characteristic patterns of a disordered personality tend to develop early in life - *if it had started 2-3 yrs back in adulthood, it is likely not a personality disorder* ## Footnote As with all personality disorders, a diagnosis of histrionic personality disorder requires that the patient demonstrate a persistent pattern of problematic behavior since early adulthood and across multiple contexts. People with ONE personality disorder often meet criteria for ANOTHER
208
**PERSONALITY DISORDERS** CLUSTER A | what happens when people from each cluster are invited to a party
"**P**a**SS**" the invitation as they: tend to shy away from social interaction  P - Paranoid  S - Schizoid  S - Schizotypal | common shared base ## Footnote Cluster A resembles psychosis
209
**PERSONALITY DISORDERS** CLUSTER B | what happens when people from each cluster are invited to a party
"**BAHN**ed" from future parties for: engaging in overly emotional, self-centered, manipulative, or even downright antisocial behaviour  B - Borderline  A - Antisocial  H - Histrionic  N - Narcisitic | all but histrionic have a shared base ## Footnote Cluster B resembles mood
210
**PERSONALITY DISORDERS** CLUSTER C | what happens when people from each cluster are invited to a party
party will be "**DOA**" (Dead On Arrival) given their tendency: to be highly neurotic, which will drag down the spirit of the party  D - Dependent  O - Obsessive-compulsive  A - Avoidant | no shared bases between disorders ## Footnote Cluster C resembles anxiety
211
**PERSONALITY DISORDERS A** *Paranoid Personality Disorder* Features
* **Low agreeableness** (tends to see people's motives with skepticism or suspisciousness) * fear * mistrust * suspiciousness * There some social engagement * usually labelled as "angry"
212
**PERSONALITY DISORDERS A** *Paranoid Personality Disorder* vs Paranoid Delusions in Schizophrenia
- Paranoia in Schizophrenia involves a **stable pattern sticking to one belief** (*fixed and enduring belief system*) - PPDs **tend to jump between various paranoid ideas** (*constant stream of new paranoid thoughts*)
213
**PERSONALITY DISORDERS A** *Schizoid Personality Disorder* Features
* **Low extroversion** (lack of interest in social relationships) * preference for solitary activities (**the happy loner** fine being on their own) * Aloof * lack of self-confidence * indiference to praise or criticism from others
214
**PERSONALITY DISORDERS A** *Schizoid Personality Disorder* vs *Avoidant Personality Disorder*
unlike in Avoidant Personality Disorder, the lack of social contact doesn't appear to bother one with Schizoid Personality Disorder. They generally find that being alone is preferable to the constant demands for connection and intimacy that others put upon them.
215
**PERSONALITY DISORDERS A** *Schizoid Personality Disorder* vs *Asociality in Schizophrenia*
The Asociality in Schizoid Personality Disorder is more *conscious* and *intentional* - ego-syntonic. In contrast, someone with schizophrenia tends to avoid social connection due to a *lack of motivation* and inability to connect with others due to *negative symptoms*
216
**PERSONALITY DISORDERS A** *Schizotypal Personality Disorder* Features
* odd beliefs (magical) & ensitive perceptions (quasi delusional beliefs) * difficulty relating to other people (emotionally distant) * eccentric behaviour * loneliness/isolation ("**isolated hippie**")
217
**PERSONALITY DISORDERS A** *Schizotypal Personality Disorder* vs *Schizoid Personality Disorder*
In Schizotypal Personality Disorder, the social avoidance is often out of fear that others will judge them for their odd beliefs, strange maneirisms, or unconventional manner of dress
218
**PERSONALITY DISORDERS B** *Narcissistic Personality Disorder*
- **High Neuroticism** (focuses on negative stimulli, thinks about mistakes from the past) - inflated self-importance (grandiosity, superiority, entitlement) - repeatedly boasting about one's sefl-accomplishment - inability to empathise (haughty, aloof) - exploits others - craves for attention and admiration - dificulty tolerating criticism ## Footnote any peoplee with narcissistic personality disorder will exagerate their claims, the disorder does not preclude them from being highly successfu, and it should nnot be assumed that they are making up or embellishing their success Although patients with (NPD) also need to be the center of attention, they typically do not exhibit the dramatic emotional displays (seen in this patient) that are a key feature of histrionic personality disorder.
219
**PERSONALITY DISORDERS B** *Narcissistic Personality Disorder* vs *Bipolar Disorder*
Look at the timing of signs and symptoms as these will be: - **enduring** in *Narcissistic Personality Disorder* - **episodic** in *Bipolar Disorder*
220
**PERSONALITY DISORDERS B** *Histrionic Personality Disorder* core Features
- excessive or exagerated behaviours intended to draw attention to one's self or to gain approval of others (*dramatic, flitartious, sexually provocative*) - although it comes shallow and provocative - Self-dramatisation, theatricality, exaggerated expression of emotions (with facial expressions and hand gestures) - **Shallow/vague speech and labile affectivity** - Continually seeking to be the centre of attention - Inappropriate disinhibition/flirtiness - Over-concern with their physical attractiveness (Uses appearance to draw attention) - easily influenced by others (suggestible) - Considers relationships more intimate than they are
221
**PERSONALITY DISORDERS B** *Histrionic Personality Disorder* other Features
- Approximately 2-3% of the population has HPD - least impairing disorder in Cluster B - **does not have association with child abuse** - F > M - **Tends to run in families** - **There's a genentic link between alcoholism and HPD**
222
**PERSONALITY DISORDERS C** *Dependent Personality Disorder* Features
* **high agreeableness** (place other's interests ahead of their own) * overreliance upon other people (clinging behaviour) * avoids conflcts * difficulty in making decisions in multiple areas of life (small and large) * seeks reassurance constantly * extremely deferential (reverential, respectful, obedient) * suggestible (can be easily influenced by other people)
223
**PERSONALITY DISORDERS C** *Obsessive-Compulsive Personality Disorder (OCPD)* Features
* **high conscientiousness** (tend towards planned behaviours) * **low openness** to new experiences (value pragamatism) * emotional rigidity and controlling behaviour * reluctant to delegate * Scrupulous * Inflexible about matters of morality
224
**PERSONALITY DISORDERS C** OCPD vs OCD
* **OCPD** - ego-systonic (feel that they are right/correct) * **OCD** - ego-dyntonic (rituals that cause feelings of distress, rather than satisfaction)
225
**PERSONALITY DISORDERS C** *Obsessive-Compulsive Personality Disorder (OCPD)* Management
- CBT - Interpersonal Therapy (addressing the effect that rigidity has on others)
226
**PERSONALITY DISORDERS C** *Avoidant Personality Disorder* Features
* creepling sense of disaproval * avoidance of social engagements * unwilingness to meet new people * - alone but wants connection * tendency to avoid getting into intimate relatioships * constant worries about being criticised or rejected * inhibited behaviour in interpersonal situatiions * a view of oneself as inept or inferior * reluctance to take risks or do anything potentially embarrassing
227
**PERSONALITY DISORDERS C** *Avoidant Personality Disorder vs Schyzoid Personality Disorder*
* **Schyzoid** - happy loner * **Avoidant** - still desire human contact
228
**PERSONALITY DISORDERS C** *Avoidant Personality Disorder* Mx
- SSRIs - CBT
229
**PERSONALITY DISORDERS** *BPD* Sings & Symptoms:
9 key criteria: **I DESPAIR**  I - **Identity**  D - **Dysphoria**  E - **Emotinal Instability** (affective lability)  S - **Suicide/Self-harm**  P - **Psychosis/Dissociative**  A - **Anger**  I - **Impulsivity**  R - **Relationships** (Unstable/Sensitivity to abandonment) = highly sensitive and specific
230
**PERSONALITY DISORDERS** *BPD* Sings & Symptoms:
**Psychosis-like** symptoms are different from primary psychosis: -- auditory hallucinations - (voices come from *inside* and are *vague*, as opposed to the typical auditory hallucinations psychosis where they they com from *outside* their head and are *clear* - often transient and tend to occur in times of stress -- paranoid ideations related to extreme interpersonal sensitivity as opposed to complex delusinal belief system
231
**PERSONALITY DISORDERS** *BPD* Sings & Symptoms:
**Impulsivity** Someone with extreme and erratic emotions would also engage in extreme and erractic behaviours these actions help to temporarily relieve the chronic state of dysphoria (as opposed to extreme bahaviours seen in mania where it is purely pleasure-seeking behaviours)
232
**PERSONALITY DISORDERS** *BPD* Sings & Symptoms:
**Splitting** Tendency to see the world in extremes or black-and-white terms. Relatives, friends, and HCPs interacting with BPD patients often find themselves on one side or the other of a split: they are either "the best person ever" or "the cruelest person ever to walk on the face of the earth"
233
**PERSONALITY DISORDERS** *BPD* Dx:
Is characterised by *chronic instability* in the domains of *identity*, *mood*, *affect*, *behaivour*, *relashionship*, and and one need **5 out of 9 sx** to be diagnosed.
234
**PERSONALITY DISORDERS** Difference between BPD and Cyclothymic disorder?
BPD: - impulsivity in at least two areas that are potentially self-damaging - A pattern of **unstable and intense interpersonal relationships** characterized by alternating between extremes of idealization and devaluation Cyclothymic: - many periods of depressed mood and many episodes of hypomanic mood for at least **2 years** - During the above 2-year period (1 year in children and adolescents), the hypomanic and depressive periods have been present for at least half the time and the individual has not been without the symptoms for more than 2 months at a time
235
**PERSONALITY DISORDERS** Difference between Dysphoria and dysthymia
* **Dysphoria** = **reactive state** people with dysphoria may express their disocontent through *anger outbursts*. They externalise their dissatisfaction thorough blaming others. * **Dysthymia** = **non-reactive** to circumstances people with depression/dysthymia may be more *passive* in their attempts to cope. They blame themselves and feel guilt
236
**PERSONALITY DISORDERS** *BPD* Mx
**Dialectical behaviour therapy (DBT)** - mindfullness - distress tolerance - emotional regulation - interpersonal effectiveness downsides - small pool of available providers (as it requires training) - Costly - time consuming (requires 1-2 years of treatment before meaningful improvements are seen) **Pharmacological** If medications must be be used, they should only be for symptomatic treatment of specific symptoms and are used adjunctively: - Anticonvulsants = reduce anger and impulsivity - Antipsychotics = alleviate paranoid or dissociative sx ## Footnote This teaches specific skills targeted towards core sympyoms that BPD patients tend to struggle with
237
**PERSONALITY DISORDERS** *BPD* and Comorbidities Mx
People with BPD often meet criteria for multiple other conditions: - depression - anxiety - bipolar disorder - PTSD **Treatment of BPD should come first**. It tends to improve related symptoms. The only exception is if there is an immediate threat to the health of the patient or if not treating these conditions it would interfere with the ability of the patient to engage in therapy
238
**PERSONALITY DISORDERS** *BPD* other features:
- evident in adolescence/early adulthood - less common in old age groups - traumatic events in child are correlated (but not causative) - F=M (although in clinical settinhs it tends to be F>M) - Family history/high inheritability (50% risk) - Complete remission is quite rare (interpersonal sensitivity tends to persist)
239
**PERSONALITY DISORDERS** *Antisocial Personality Disorder (ASPD)* Sings & Symptoms:
8 criteria "**ACID LIAR**"  A - **Adult** (diagnosis > age of 18)  C - **Criminality**  I - **Impulsivity** (low conscientiousness)  D - **Disregard for safety**  L - **Lying**  I - **Irresponsibility**  A - **Aggression**  R - **Remorselessness**
240
**PERSONALITY DISORDERS** *Antisocial Personality Disorder (ASPD)* other features
- emotinal instability (anger, sadness, irritability) - impulsive aggression - difficulties in relationships - isolation and loneliness - premaditated acts
241
**PERSONALITY DISORDERS** *Antisocial Personality Disorder (ASPD)* Dx
Adult age + 3 or more of the core symptms
242
**OPOSITIONAL DEFIANT DISORDERS (ODD)**
DOs - Argumentativeness (frequently argues/stubbornness) - purposefully do things to upset others - vindictiveness - defiance/testing limits (ignore rules) - Failing to accept responsibility for one’s own actions and blaming others for one’s own mistakes. DON'Ts - violate others rights - no overt violence - no aggression - no theft ## Footnote must occur for at least 6 months
243
**OPOSITIONAL DEFIANT DISORDERS (ODD)** Other features
- average onset age 6-8 years (can continue into adolescence) - M > F (2x) - persistent anger and irritability (losing one’s temper) - believe that they are justified in their actions
244
**CONDUCT DISORDER (CD)**
- Flaglrant disregard to others' rights - overt violence (physical cruelty) - aggression (fights) - robbery, fire setting, property damage - sexual coercion ## Footnote conceptualised as a precursor to ASPD
245
**CONDUCT DISORDER (CD)** other features
- almost all patiets show signs by the age of 10 - M > F (4x) - believe that they are justified in their actions
246
**Externalising Disorders (ODD,CD)** Mx
- family therapy - behavioural training for the child - medications are geneerally not helpful CD reponds to a lesser extent than ODD to these therapies
247
**Eating Disorders** Eating disorders are commonly associated with what patient profiles (history)
– Female Adolescent – Low self-esteem – Personal or family history of depression – Family history of obesity – High personal expectations – Family history of eating disorders – Disturbed family interactions - Social factors - Childhood sexual abuse - Perfectionism and obssessionality
248
**Eating Disorders** *Anorexia Nervosa* core patterns
"**UNDER**-exia"  U - **Underweight** (BMI < 17.5)  N - **Nervous/fearful** about gaining weight  D - **Distorted** self-perceptions about weight (ego-syntonic)  E - **Exercise/purging/other behaviours** to burn calories and lose weight  R - **Restricting** caloric intake
249
**Eating Disorders** *Anorexia Nervosa* Lab features
- Significant electrolyte disturbance (K < 3.0 or Na < 130) - Hypercholesterolemia - Raised liver enzymes and Albumin < 35g/L - Vitamin deficiencies - LOW WBC - Hypochloraemic Alkalosis - ESR is LOW or Normal
250
**Eating Disorders** *Anorexia Nervosa* Clinical features
- Bradycardia. (< 40bpm) - Hypotension (< 90mmHg) - Dehydration (excessive exercise/abuse of laxatives) - osteoporosis - Amenorrhoea/Infertility (abscence of 3 consecutive cycles) -- secondary amenorrhoea due to low levels LH/FSH (hypogonadotropic Hypogonadism) - Constipation - Cachexia (less than 85% of ideal body weight) - Hypothyroidism -- Hypothermia -- Cold intolerance - mood swings, anxiety - **Suicide** (single most deadly mental ilness, with up to 20% of people dying) | https://pubmed.ncbi.nlm.nih.gov/22349551/ ## Footnote can be associated with: -Depression -OCPD
251
**Eating Disorders** *Anorexia Nervosa* Indications for hospital admission
 Low weight (85% or less of expected weight and/or less than the third percentile for BMI) Physiologic decompensation including, but not limited to, the following:  severe electrolyte imbalance (life-threatening risks created by sodium and potassium derangements),  cardiac disturbances or other acute medical disorders  orthostatic differential > than 30/min  Temperature < than 36°C  Pulse < 45 bpm  Significant oedema  altered mental status or other signs of severe malnutrition  Psychosis or a high risk of suicide
252
**Eating Disorders** *Anorexia Nervosa* vs *OCD*
- Anorexia = ego-syntonic (lack of insight) - OCD = ego-dystonic
253
**Eating Disorders** *Anorexia Nervosa* & OCPD
- ego-syntonic - rigitiy of behaviour (little variation) - high conscientiousness (act in accordance with societal expectations ## Footnote Anorexia has a high rate of comorbity with OCPD
254
**Eating Disorders** *Anorexia Nervosa* Epidemiology/Risk Factors
- F > M (10x) - begins around puberty (13-14y) and young adulthood (17-18y) - Associated with careers/hobbies that can produce extrem pressure to be thin (modeling, gymnastics, ballet, and running) - low self-esteem - high socioeconomic status (SES)
255
**Eating Disorders** *Anorexia Nervosa* Mx
- nutritional rehabilitation - psychitherapy (CBT) - Medications are of no proven benefit for the primary anorexia nervosa itself.
256
**Eating Disorders** *Anorexia Nervosa* severe complication related to re-initiation of nutrition
**Refeeding Syndrome** ## Footnote The manifestations of refeeding syndrome are mainly caused by hypophosphataemia, precipitated by increased glycolysis when carbohydrate replaces body fat as the main source of energy. In chronic malnutrition, phosphate stores are already low. When the individual is suddenly fed again, insuline is released causing further uptake of phosphate into cells and leads to even grater hypophosphatemia. The low availability of phosphate prevents metabolic intermediates from being produced, leading to hypoxia and muscle disfunction.
257
**Eating Disorders** *Refeeding Syndrome*
- cardiovascular collapse, cardiac failure - rhabdomyolysis and muscle weakness (which in turn may lead to ventilatory failure, seizures or delirium) - Hypokalaemia and hypomagnesaemia can cause cardiac arrhythmias - glycolysis-induced thiamine depletion can lead to Wernicke encephalopathy
258
**Eating Disorders** *Refeeding Syndrome* Patients at high risk of developing refeeding syndrome if they have:
**one or more of the following**: - BMI < 16 - loss > 15% of body weight in the last 3-6 months - little or no nutritional intake for > 10 days - low concentrations of potassium, phosphate or magnesium before reintroduction of nutrition OR **two or more of the following**: - BMI < 18.5 - loss > 10% of body weight in the last 3-6 months - little or no nutritional intake > 5 days - history of hazardous alcohol use or drug use (including insulin, chemotherapy, antacids or diuretics).
259
**Eating Disorders** *Refeeding Syndrome* Management of refeeding syndrome
- **Give thiamine** (at least 100 mg IV or 300 mg VO, daily) before starting and for the first 7-10 days of feeding. - **Measure serum electrolytes** (including potassium, phosphate, and magnesium) before starting feeding, and supplement as required. Check serum electrolytes at least daily for the first week after reintroduction of nutrition. - **Start feeding slowly** (30-50% of estimated caloric requirement) then, if electrolytes are stabilised, increase gradually over 5 to 7 days to the patient’s estimated needs. For severely malnourished patients, start at 5-10 kcal/kg/day. - **Give a multivitamin** (once daily for at least 7 days). - In the first week of refeeding, **monitor vital signs** and (in high-risk patients) cardiac rhythm, and look for signs of oedema, heart failure and a deteriorating mental state.
260
**Eating Disorders** *Bulimia Nervosa* Signs & symptoms
**Bowl**-emia  B - **Binge eating** (impulsive/out of control)  O - **Off-setting** behaviours (purging)  W - **Weekly** (or more) **for** a period of **3 months**  L - **Linked** to self-steem ## Footnote Purging (methods inteded to rid the body of the effects of calories) can take form in different behaviours: - self-induced vominting (most common) - Laxatives/diuretic/enema abuse - driven exercise and/or fasting
261
**Eating Disorders** *Bulimia Nervosa* complications due to purging
- Kidney injury due to dehydration - Metabolic Alkalosis (loss of stomach acid) - gastric ulcers - Boerhaave Syndrome - changes in hormone levels (amenorrhoea is common, but no hirsutism) - abnormalities in liver and thyroid function, and anemia are a result of malnutrition seen in Anorexia nevorsa, hence less likely Bulimia Nervosa Physical exame: - Patients have normal weight or are overweight (BMI > 18) - erosion of dental enamel/dental decay - swollen salivary glands - injury of the knuckles (Russell's sign) ## Footnote The menstrual and ovulatory abnormalities are due to suppresed sex hormone secretion as a consequence of fasting and prolonged dietary restriction
262
**Eating Disorders** *Bulimia Nervosa* Epidemiology/Risk Factors
- F > M (10x) - peak onset at 18 (but can begin in adolescene, or as old as 25 years) - Family history of eating disorder - associated with sexual abuse - often comorbid with BPD
263
**Eating Disorders** *Bulimia Nervosa* Mx
- CBT + Interpersonal Therapy - SSRIs (for both depressed and not depressed patients)
264
**Eating Disorders** *Bulimia Nervosa* Mx which SSRI must be avoided and why?
Bupropion - Increases the risk of seizures
265
**Somatoform Disorders** *Somatic Symptom Disorder* Dx
History of many physical complaints begining before the age of 30 "**SOME-ATTIC**"  S - **Symptoms**  O - **One** or multiple  M - **Medically** unexplained ("no outward sign")  E - **Excessive**  A - **Anxiety** about health or symptoms  T - **Thinking** about the seriousness of symptoms  T - **Time** and energy devoted to these symptoms or health concerns  I - **Impaired** or distressed resulting in significant disruption of daily life  C - **Chronic** the state of being symptomatic is persistent, lasting months to years (typically more than 6 months) ## Footnote -gastrointestinal tract is the most commmon location for somatic symptoms in ALL PATIENTS -gynecologic complaints are the second most common symptom IN WOMEN 1. **FOUR Pain symptoms**: Headaches, abdominal pains, back and joint pain, pain during menstruation or sexual intercourse, chest pain. 2. **TWO GI symptoms**: Nausea, bloating, vomiting other than during pregnancy, diarrhea or intolerance to several foods. 3. **ONE sexual symptom**: Erectile dysfunction, irregular menses, excessive menstrual bleeding, vomiting throughout the pregnancy. 4. **ONE Pseudoneurologic symptom**: Conversion symptoms such as impaired coordination or balance, paralysis or localized weakness, difficulty in swallowing, lump in throat, aphonia, hallucinations, loss of sensations, visual problems, urinary retention etc. Either of the following: 1.After appropriate investigations, symptoms not adequately explained by known general medical condition. 2.When related to a general medical condition, symptoms are In excess of what would be expected from history, physical examination and investigations.
266
**Somatoform Disorders** *Somatic Symptom Disorder* Mx
- Regular visits (minimises the idea of only seeing the doctor when sick) - CBT - Midnfulness therapy - physiotherapy & rehabilitation - TCA's and SNRIs (smaller effect) ## Footnote Analgesia is usually not helpful
267
**Somatoform Disorders** *Conversion Disorder* Dx
"**CAN'T**-version  C - **Clinically** unexplained  A - medical **Abnormality**  N - involving **Nervous System**  T - usually (~50%) brought on by a **Trigger** ## Footnote Patient is not manufacturing or faking the symptoms (*unconscious & Involuntary*)
268
**Somatoform Disorders** *Conversion Disorder* Features of neurologic sx
- subjectively reported symptoms (blindness, blurry vision, loss of sensation) - objectively observed signs (weakness, imbalance, shaking) OR - absence of function (as in motor paralysis) - presence of dysfunction - (as in convulsions) ## Footnote NOTE: given the features above, the conversion disorder diagnosis would not be appropriate a patient presenting with abdominal pain or chest discomfort)
269
**Somatoform Disorders** *Conversion Disorder* Mx
- Educate patient about conversion disorder - overall majority of cases resolve spontaneously - physical/occupational therapy can be helpfu for patients with motor deficit (even in the absence of objective neurologic pathology) - 25% relapse within a year NOTE: CBT and medication are **not helpful**
270
**Somatoform Disorders** *Factitious Disorder* Signs & Symtpoms
unexplained symptoms intentionally feigned - **intentional** production of symtpoms voluntary - **Unsconscious** goal is primary gain (desire the sympathy and attention that accompanies having an illness) - Recurrent presentations - rejects being discharged - Knowledge of illness (50% work in the medical field)\ - No insight (can hurt themselves; desire to remain in the sick role over and above preserving their own bodily integrity) "**FAC**" - F - Factitious - A - Always - C - come back as their primary motivation is in the medical care itself
271
**Somatoform Disorders** *Factitious Disorder* associated with self-harm?
- Munchausen Syndrome (intentional self-inflicted harm to provide evidence of illness. Can also be someone who knownly has a condition but refuses treatment to gain others' sympathy) - Munchausen Syndrome by proxy (harm imposed on another)
272
**Somatoform Disorders** *Factitious Disorder* Mx
- poor prognosis - neither medications nor psychotherapy are effective - Refer to specialist
273
**Somatoform Disorders** *Malingering* Signs & Symtpoms
**intentional** and **Conscious** production of signs and symptoms for obvious secondary gains. - - goal is extrinsic to the role of being sick (disability payments, excuse from work/military service, lighter sentence in a criminal case, financial compensation from a fake injury, admission to hospital) "**MAL**" - M - Malingering - A - Always - L - Leave once their need has been met, because there is no longer reason for them to seek medical care
274
**Somatoform Disorders** *Malingering* Mx
No clear treatment
275
Difference between Complicated Grief Disorder & Avoidant personality disorder?
Complicated grief: - symptoms persist longer than six months - Avoidance of situations that serve as reminders of the loss is also common Avoidant Personality Disorder:
276
CATATONIA symptoms
- lmmobility or excessive purposeless activity - Mutism, stupor (decreased alertness & response to stimuli) - Negativism (resistance to instructions & movement) - Posturing (assuming positions against gravity) - Waxy flexibility (initial resistance, then maintenance of new posture) - Echolalia, echopraxia (mimicking speech & movements) Rx: Hospitalisation + Benzodiazepines
277
**CATATONIA** most often develops in the context of??
a mood disorder (eg, bipolar disorder, major depressive disorder)
278
**CATATONIA** 1st line treat for malignant catatonia?
ECT
279
Tardive dyskinesia vs Parkinsons disease
identical symptoms: - rigidity - bradykinesia - postural instability Differentiating symptoms: - involuntary movements of face and tongue (tardive) - Stiffness
280
**Dementia** Dx
"**DIRE**"  D - **Decline** in cognition (memory, language, hability to plan) - screening tools (e.g. MMSE, MoCA)  F - Functional **Impairment** (IADLs 1st > ADLs 2nd)  R - **Rule** out Delirium  E - **Exclude** other mental health conditions
281
**Dementia** vs "*Normal aging*"
Normal aging **Preserved** cognitive domains - language - recognition of faces and situations - awareness of memory loss Normal aging **Impaired** cognitive domains - deficits in short-term memories - declarative memories (recalling) - attention - processing speed - concrete thinking (as opposed to ability to think abstractly)
282
**Dementia** What are IADL's
Intrumental Activities of Daily Living (first signs of the impact of cognitive impairments) "**SHAFT**"  S - **Shopping**  H - **Housekeeping**  A - **Accouting**  F - **Food Preparation**  T - **Transportation**
283
**Dementia** What are the ADL's"
Activities of daily living: (signs of late stage cognitive impairment) "**DEATH**"  D - **Dressing**  E - **Eating**  A - **Ambulating**  T - **Toileting**  H - **Hygiene**
284
**Dementia** What is MMSE
**Screening** tool to assess **cognitive** skills
285
**Dementia** What are the 5 main areas assessed on the MMSE
"**ORRAL**"  O - **Orientation** (time/space)  R - **Registration** ("name 3 objects)  R - **Recall** (ask for the 3 objects repeated above)  A - **Attention/Concentration & Calculation**  L - **Language**
286
**Dementia** Examples of methods used to assess Attention/Concentration on the MMSE
- serial 7's (from 100 - 0) **not a memory test** - spelling a word backwards **not a memory test** - serial 3's (from 100-70) **not a memory test** - Digit span **memory test** - Recitation of the days of the week/mothns of year in reverse order) **not a memory test**
287
**Dementia** What MMSE score would indicate a normal test?
25-30
288
**Dementia** What would a score of 24 on an MMSE indicate?
pseudodementia/depression
289
**DEMENTIA** Difference between dementia & pseudodementia?
Cognitive impairment due to the presence of a mood-related mental health concern, most often depression (giving up). Pseudodementia have **INSIGHT**
290
**Dementia** If patient has scored just below the normal threshold of MMSE due to sight impairment. What should be done?
Correct sight impairment and redo test, or perform other cognitive tests that do not require sight (Six-item Cognitive Impairment Test)
291
**Dementia** What does a score < 25 on the MMSE indicate?
Cognitive decline
292
**Dementia** After MMSE is done to determine cognitive decline what investigation is best indicated?
it is improtant to: - rule out delirium - exclude other psychiatric conditons (e.g. depression) - CT (PET) scan (the presence of brain tissue degeneration, such as atrophy, can confirm dementia)
293
**Dementia** What is the Clock Drawing Test (CDT)
Although it is part of a screening tool for congnitive impairment (MoCA), the CDT t is a tool that **measures dementia severity** strong indicator of early dementia, but it can't diagnose the type of dementia or rule out other conditions
294
**Dementia** What cognitve(s) domain(s) is(are) assessed on the Clock Drawing Test
- Frontal functioning - Temporo-parietal Functioning
295
**Dementia** Types of dementia
- Alzheimer's Dementia (50% to 70%) - Non-Alzheimer's Dementias -- Frontaltemporal dementias (up to 10%) -- Dementia with Lewy Bodies and Parkinson disease dementia (up to 10%) -- Vascular Dementia (10% to 20%) -- alcohol-related dementia (up to 5%).
296
**Dementia** *Alzheimer's Dementia* S/Sx + Dx
No single test to diagnose Alzheimer’s "**GRANdPA U OK**"  G - **Gradual** decline  R - **Relentless** (unremiting, steady downward Trajectory)  A - **Amnesia** ( + Neurocognitive deficits = 4 A's)  Nd - **Neurocognitive deficits**  P - **Psychiatric** (mood changes, psychosis-like sx)  A - **Activity** (losses in complex behaviours, increase in purposeless behaviours)  U - **Unable** to function  O - **Objective** biomarkers  K - **Knowledge** of Illness (patients are unware of their cognitive defits)
297
**Dementia** *Alzheimer's Dementia* the 4 A's of Neurocognitive Deficits
 4 A’s of Alzheimer's: -- **Amnesia** (EARLY SYMPTOM defining feature of the condition) -- **Aphasia** (LATER FINDING; language impairment - sepaking, reading, writing, and receptive) -- **Apraxia** (LATER FINDING; inability to perform motor activities) -- **Agnosia** (LATER FINDING; inability to translate what we percieve with our senses into a cohesive signal to be acted upon) ## Footnote Progression of cognitive impairment follows this order: Amnesia > Aphasia, > Apraxia > Agnosia
298
**Dementia** *Alzheimer's Dementia* Amnesia features
- FIRST and MOST affected cognitive domain - both retrograde and anterograde memories affected (with the former being impacted earlier and more severely) these distintinctions tend to breakdown as the disease progresses
299
**Dementia** *Alzheimer's Dementia* What is "*sundowning*"
State of confused restlessness/agitation/wandering that is more prominent in the evening Endeavour to manage sundowning through nonpharmacological interventions.
300
**Dementia** *Alzheimer's Dementia* Imaging
 *CT scan* -- widespread cortical atrophy -- widespread decrease in brain cells metabolic activity -- hypocampus atrophy (low Acetylcholine activity)
301
**Dementia** *Alzheimer's Dementia* Pathology Biomarkers
 pathology (not routinely done) * cerebral spinal fluid -- B-amyloid protein -- Tau Protein * biopsy -- senile plaques (clumps of B-amiloid ptrotein) -- neurofibrilary tangles (Tau Protein)
302
**Dementia** *Alzheimer's Dementia* genetic Biomarkers
 genetic testing (autosomal dominant) * APOE4 gene (codes for a poorly fuctioning version of APO-LIPOPROTEIN E which clears B-amyloid protein) --- 1 copy = 3x more risk --- 2 copies = 15x more risk
303
**Dementia** *Alzheimer's dementia* Epidemiology/Prognosis
- early onset considered < 65 years - risk 3% in population > 65 years - risk doubles every 5 years - Steadily progressive; No cure - highly lethal (death occuring with 10 years of dx)
304
**Dementia** *Alzheimer's dementia* Nonpharmacological Mx
****goals of treatment are: - paliative - symptom reduction - preservation of function Psychotherapy not effective (cognitive deficits prevent patient from meaningfully engaging in treatment)  Behavioural modifications -- education -- self-care (bathing, dressing, toileting) -- exercise  Sensory stimulation- music, pets.  Social interaction- regular visits from family, friends. ## Footnote Patients with a clinical suspicion for dementia should not be permited to driveor operate complex machinery that could potentially put their own lives or the lives of others at risk.
305
**Dementia** *Alzheimer's dementia* Pharmacological Mx
1. Cholinesterase inhibitors (AChEi) (**donepezil, galantamine, rivastigmine**) 2. NMDA receptor antagonist (memantine) ## Footnote * These drugs improve alertness and function and can maintain cognitive scores at or above the baseline for up to 12 months; * Not all patients benefit from cholinesterase inhibitors; some have modest benefit and a few show significant improvement. * Patients should be treated for at least 2 months at the maximum recommended dose (if tolerated) before a final assessment of response is made. * If patients tolerate and appear to benefit from cognitive enhancing drugs then the drug should not be ceased until the patient is in an advanced state of dementia (usually having lost independent mobility)
306
**Dementia** *Alzheimer's dementia* Pharmacology: Tocxicity of AChE Inhibitors
"**DUMBBEELSS**"  D - **Diarrhoea**  U - **Urination** (urinary incontinence)  M - **Miosis**  B - **Bradycardia**  B - **Bronchocontriction**  E - **Emesis**  E - **Excitation** (tremor, insomnia,vivid dreams)  L - **Lacrimation**  S - **Salivation**  S - **Sweating** other side associated with prominent adverse effects are: * anorexia, weight loss * depression * lethargy, fatigue, drowsiness Take care when introducing these drugs in patients with: - asthma, chronic obstructive pulmonary disease (**Bronchoconstricion**) - cardiac conduction abnormalities (particularly atrioventricular block) (**Bradycardia**) - **peptic ulcer disease**
307
**Dementia** *Alzheimer's dementia* Pharmacology: NMDA Inhibitors adverse effects
- confusion - dizziness - drowsiness - headache - insomnia (If present, memantine can be taken earlier in the day) - agitation and hallucinations NOTE: reduce dose in kidney failure (RENAL EXCRETION)
308
**Dementia** "*Dementia with Lewy Bodies (DLB)*" S/Sx
"**C'N STUPH**"  C - **Cognitive deficits** fluctuation (memory isn't the most prominent cognitive domain that is affected - in contrast to Alzheimer's)  N - **Neuroleptic sensitivity** ( poor response and at higher risk of developing side effects to antipsychotics) AVOID!  S - **Sleep bahviour** (REM Sleep Behaviour disorder - patients acting out on their dreams) - **very specific sign**  T - **Timing** (earlier onset, rapid decline)  U - **Unstable** (rapid fluctiation in cognition, waxing and waning alertness and lucidity) - very specific  P - **Parkinsonism** (tremor, rigidity, slow movement, postural imbalance, ataxic gait)  H - **Hallucinations** (visual)
309
**Dementia** "*DLB*" vs "*Alzheimer's dementia*"
**Alzheimer's** - onset usually > 65 - gradual and progressive decline (years) - memory is usually the first cognitive domain to be affected **DLB** - earlier onset (~50s) - rapid cognitive decline (months) - cognitive domains other than memory are prominently affected - Fluctuating confusion - visual hallucinations - EPS
310
**Dementia** "*DLB*" vs "*Schizophrenia*" hallucinations
**DLB** - insight is usually preserved (patient not bothered) - Typically visual hallucinations **Schizophrenia** - no insight, severely disturbed - Auditory hallucinations are prevalent
311
**Dementia** "*Dementia with Lewy Bodies (DLB)*" Mx
Similar to Alzheimer's dementia (but less effective and impose greater side effect burden) - anti-Parkinson's drugs to treat motor symptoms
312
**Dementia** Charles-Bonnet Syndrome (CBS):
 Intact cognition/preserved insight  Ocular Pathology (BLIND or, commonly, macular degeneration) or occipital disease - NOT psychiatric  Visual Hallucination - vivid, colourful, and well-organised hallucinations - experience may last for seconds or hours at a time - patient has good insight - hallucinations are not distressing, but may be quite engaging
313
**Dementia** "*Frontotemporal Dementia (FTD)*" S/SX
"**OH DEAR**"  O - **Obliviousness** (loss of sympathy and empathy, tactlessness)  H - **Hyperorality** (preference for carbohydrate-rich foods, consumption of inedible objects)  D - **Disinhibition** (impulsivity, hypersexuality, loss of social awareness)  E - **Executive dysfunction** (language difficulty, inability to plan and execute complex ideas)  A - **Apathy**  R - **Restrictive/ritualistic behaviour** * **Insidious onset and slow progression** * early changes are in personality & behaviour * memory and visuospatial abilities are relatively preserved (to laste-stage disease) - *in constrast* with Alzheimer's * not same fluctiation seen in DLB
314
**Dementia** "*Frontotemporal Dementia (FTD)*" Dx
- (Clock Drawing Test) CDT is a screening tool and a cognitive deficit score (SCORE ≥ 3) on this test can indicate FDT
315
**Dementia** "*Frontotemporal Dementia (FTD)*" Mx
- tailored behavioural management strategies - TG does not recomend any pharmacotherapy for FTD
316
**Dementia** "*Vascular Dementia*" Clinical Features
- **sudden cognitive decline in a step-wise manner (each drop in functional ability represents another ischemic event)** - emotinal lability - gait abnormalities - urinary dysfunction - Parkinson motor features - Hallucinations are rare/not present - Vascular lesions on CTI/MRI
317
**Dementia** "*Vascular Dementia*" Risk Factors
- HAS - DM - CVD - smoking - hyperlipedemia
318
**Dementia** Reversible causes of dementia-like symptoms
"**DEMENTIAS**"  D - **Dringking & Drugs**  E - **Endocrine** (thyroid, parathyroid, pituitary, adrenal)  M - **Metabolic** (disglycemia, electrolytes, vitamin b12 deficiency)  E - **Ears & Eyes** (sensory impairment)  N - **Neoplasias**  T - **Trauma** (subdural hematoma)  I - **Infection** meningitis, encephalitis, Endocarditis, syphilis, HIV)  A - **Autoimmune**
319
**Dementia** "*Normal Pressure Hydrocephalus*"
Triad "**DIG**"  D - **Dementia**  I - **Incontinence**  G - **Gait** ## Footnote Mx: shunt to drain excess fluid
320
**Dementia** Treatment of mood and behavioural disturbances in dementia
- **AVOID** First-Generation Antipsychotics (FGA) * **Anxiety and agitation** -- Oxazepam VO * **hallucinations, delusions or seriously disturbed** -- 1 Risperidone VO OR -- 2 Olanzapine VO * **Depression** -- **Avoid** antidepressants with anticholinergic adverse effects (i.e. **TCA's**) (exaggerate the cognitive deficits due to central acetylcholine deficiency in Alzheimer disease)
321
**Dementia** "*Wernicke's Encephalopathy*" Pathophysiology
**Acute** neuropsychiatric reaction to severe thiamine deficiency. It is a type of delirium and is usually reversible
322
**Dementia** "*Wernicke's Encephalopathy*" Sx:
TRIAD: - CONFUSION - GAIT ATAXIA (Lack of coordination) - OPHTHALMOPLEGIA (horizontal nystagmus, abducens palsy, or conjugate gaze disorder all typical). -- **All three elements of this triad need not be present in order to make the diagnosis. **
323
**Dementia** "*Wernicke's Encephalopathy*" Conditions that can lead to B1 deficiency
Thiamine deficiency may be secondary to: - alcoholism - Hyperemesis gravidarum - restrictive eating disorders + vomiting - cannabis hyperemesis Syndrome - dietary deficiency associated with Mg insufficiency - gastric carcinoma
324
**Dementia** "*Wernicke's Encephalopathy*" Mx:
urgent IV thiamine
325
**Dementia** "*Wernicke's Encephalopathy*" if not treated?
but the majority will develop a chronic Korsakoff syndrome.
326
**Dementia** "*Korsakoff syndrome*" Pathophysiology
**Irreversible** damage to the mammillary bodies (region associated with memory and recall) leading to **Dementia**
327
**Dementia** "*Korsakoff syndrome*" Sx
- profound **anterograde** amnesia - Confabulation (due to memory gaps)
328
**Dementia** "*Huntington's Disease"*
- 20 - 50 years old - Dementia - Chorea
329
**Dementia** "*Huntington's Disease"* Who can have the presymptomatic genetic test?
According to international guidelines: * people ≥ 18 years or older **AND** * have a blood relative who has been diagnosed with HD ## Footnote https://www.genetics.edu.au/PDF/Huntington_disease_genetic_testing_booklet-CGE.pdf
330
**Dementia** "*Creutzfeldt-Jakob Disease (CJD)*" Sx
- mid-aged adults - rapidly progressive dementia (weeks - months) - **Myoclonus**
331
**Delirium** ("*Acute Confusional State*") Screening/Dx
The Confusion Assessment Method (CAM) considers that a diagnosis of delirium is likely if the following are present: - acute onset and fluctuating course - impaired attention span (or inattention) - disorganized thinking or an altered level of consciousness.
332
**Delirium** Risk Factors
- age > 65 years - pre-existing dementia
333
**Delirium** Precipitants
 D - **Drugs** & **Drug Withdrawal** -- prescription and over-the-counter medicines, and alcohol and illicit drugs -- withdrawal states - alcohol and benzodiazepines; (suspect alcohol withdrawal if tremors, sweating and visual hallucinations are present)  E - **Epilepsy** & **Endocrine** -- seizures and postictal states -- DM, Thyroidism  L -  I - **Infections** (UTI most common in AUS)  R -  I - **Intracerebral** events (subdural haematoma, haemorrhage, stroke)  U - **Unpleasantness** (pain and discomfort, urinary retention, constipation)  M - **Metabolic disturbance** & **Malignancy** (hypoglycaemia, hyperglycemia, hyponatraemia)  organ failure: kidney failure, liver failure, and respiratory failure with hypoxia/hypercapnia  cardiac events: MI, arrhythmia, CHF ## Footnote Deafness is a well documented predisposing factor to paranoid illness in elderly people. Characteristically, this complicates severe bilateral deafness resulting from middle ear disease and chronic mastoiditis.
334
**Delirium** Drugs and drug groups commonly implicated in delirium
 A - **alcohol and illicit drugs** (eg cannabis, methamphetamine).  A - **Anticholinergics**  B - **Benzodiazepines**  C - **corticosteroids**  D - **dopaminergic drugs** - NSAIDs - Opioids - sotalol and propranolol (unlikely with other beta blockers)
335
**Delirium** Emergency Mx
DRABCDE + TONGF ## Footnote The delirious patient must be observed at all times.
336
**Delirium** Pharmacological management
Haloperidol VO (single dose) OR olanzapine VO (single dose) OR Risperidone VO (single dose) ## Footnote *onset of action can be delayed from 30-60 minutes after administration *second doses should not be given for at least 30 minutes
337
**Delirium** Pharmacological management | If oral administration is impossible and symptoms are severe
Haloperidol IM (single dose) OR Olanzapine IM (single dose) ## Footnote *onset of action can be delayed from 30-60 minutes after administration *second doses should not be given for at least 30 minutes
338
**Delirium** What drug should be avoided
**benzodiazepines** should be avoided in delirium (especially in patients with significant respiratory depression) *except for cases due to alcohol withdrawal or seizures*
339
**Delirium Tremens** (or Alcohol Withdrawal Delirium) Sx:
- It usually commences **72 to 96 hours (3-7 days)** after cessation of drinking. - characterised by: -- **gross tremors** -- fluctuating levels of agitation -- **hallucinations (usually tactile)** -- disorientation and impaired attention -- Fever -- tachycardia -- hypertension -- dehydration it is usually associated with: -- infections -- anaemia -- metabolic disturbances -- head injury
340
**Delirium Tremens** Mx:
1 diazepam VO 2 midazolam IV (if **agitation**) If an **antipsychotic** drug is required, use: - VO Haloperidol **AVOID chlorpromazine** (it lowers seizure threshold) If **extrapyramidal adverse effects** (EPS) emerge: - benztropine VO or IM ## Footnote IV diazepam should be avoided if possible -- Onset of action is not much faster than with VO -- there is a greater likelihood of causing severe adverse effects such as respiratory depression -- If an injection is necessary, it must not be diluted and it must be given slowly over several minutes to minimise the risk of respiratory depression or arrest.
341
**Delirium Tremens** Mx: | **For severe psychotic symptoms when VO not possible**
- - Haloperidol IM, as a single dose. (less likely to lower seizure threshold) OR - - Droperidol IM, as a single dose (similar to haloperidol but is more sedating)
342
**Sleep Disorders** "*Insomnia*" types
- Idiopathic (Primary) Insomnia - Secondary Insomina According to duration: - Acute Insominia (< 30 days) - Chronic Insomina (> 30 days)
343
**Sleep Disorders** "*Insomnia*" Idiopathic Insomnia mechanism
- over-reactivation of HPA axis - Hypervgillance about falling asleep
344
**Sleep Disorders** "*Insomnia*" Secondary Insomnia mechanism
A symptom of other disorders * due to somatic symptoms (pain) * Psychiatric Conditions (mood and anxiety disorders) * Drug use (caffeine, alcohol, nicotine being more common) * Intrisic Sleep Disorders ( sleep apnoea, restless legs syndrome)
345
**Sleep Disorders** "*Insomnia*" FIRST LINE Mx
Primary treatment goals are to improve sleep quality and quantity, and to relieve insomnia-related daytime impairment. - Management of underlying problems - Good sleep practices (sleep Hygiene) -- Sleep–wake activity regulation -- Sleep setting and influences -- Sleep-promoting adjuvants - Psychological and behavioural interventions (most often used for chronic insomnia as they do not work immediately and require practise and persistence) -- Relaxation therapy --- e.g. hypnosis, meditation --- can be of benefit for both acute and chronic problems -- Cognitive therapy (CBTi - "i" for insomnia) --- targets dysfunctional beliefs about sleep -- Stimulus control --- limit the amount of time spent in bed awake --- useful for people who have difficulty falling asleep -- Sleep restriction --- goal is to reduce the amount of time spent awake --- suitable for people who have difficulty staying asleep due to poor sleep drive.
346
**Sleep Disorders** "*Insomnia*" Pharmacologic Mx indications
- short-term management of **acute insomnia** - **chronic insomnia** when the nonpharmacological strategies are not effective.
347
**Sleep Disorders** "*Insomnia*" hypnotic drugs
1 Temazepam VO (before bedtime) (idel for patients with sleep onset insomnia) OR 1 Zolpidem VO (less morning sedation) OR 1 Zopiclone VO OR 2 Melatonin VO (before bedtime) for patients > 55 years (there is insufficient evidence to support treatment > 3 wks) ## Footnote Contra-indicated if history of: - addiction and dependence - OSA - use of other substances (e.g alcohol, CNS depressants) Complaints of use of BZ include: - sleeping is not refreshing - reduced daytime alertness
348
**Sleep Disorders** "*Insomnia*" Treatment duration and Mx of long-term hypnotic use
- treatment should be limited to < 2 weeks. - Intermittent therapy may be considered in severe longstanding insomnia that is not relieved by non-pharmacological management ## Footnote The patient with chronic insomnia should be reviewed weekly for 4-6 weeks period for these psychological and behavioural treatments.
349
**Sleep Disorders** "*Parasominas*" Definition
Dysfunctions associated with sleep, sleep stages or partial arousal + abnormal motor, behavioural or sensory experiences.
350
**Sleep Disorders** "*Parasominas*" main Types
- occurring in **non-REM sleep** -- associated with stages 3 and 4 -- typically occur in the first half of the sleep period -- eg sleepwalking, sleep terrors - associated with **REM sleep** (eg nightmares, REM sleep behaviour disorder)
351
**Sleep Disorders** "*Sleepwalking*" features
* sleeper performs some repetitive activity in bed * sleeper can walk freely from the bed * more common in children * can be associated with some hypnotics
352
**Sleep Disorders** "*Sleepwalking*" Mx
- Usually no treatment is required - if frequent, and presents danger sleeper, the sleeping environment should be made safe. - Adults with recurring episodes may need to seek specialist assistance. Hypnotics may be considered if: * have injured themselves or others * serious risk of doing so * whose quality of life is significantly affected.
353
**Sleep Disorders** "*Night (Sleep) Terrors*" features
- sharp screams - violent thrashing movements - autonomic discharge with sweating and tachycardia. - **The subject may or may not wake** - **there is usually no recall of the event** (as they occur in non-REM sleep states)
354
**Sleep Disorders** "*Night (Sleep) Terrors*" Mx
- Usually no treatment is required (vast majoirty do not persist into adulthood) - reassurance is typically sufficient - Adults with recurring episodes may need to seek specialist assistance. Hypnotics may be considered if: * have injured themselves or others * serious risk of doing so * whose quality of life is significantly affected.
355
**Sleep Disorders** "*Nightmares*" features
- dream-related anxiety episodes - Recurrent stereotyped nightmares are commonly associated with PTSD - can be associated with the discontinuation of REM-suppressing drugs (eg alcohol, antidepressants and some hypnotics) - A number of drugs can also cause vivid dreams or nightmares (eg B-blockers, SSRIs, benzodiazepines, levodopa)
356
**Sleep Disorders** "*Nightmares*" Mx
- Psychological evaluation and therapy are required if associated with PTSD
357
**Sleep Disorders** "*REM Sleep Behaviour Disrder (RBD)*" features
- complex and elaborate motor activity in association with dreams - may result in violent behaviour during sleep - **frequently associated with neurodegenerative (eg Parkinson's and Lewy Bodies Dementia ** Diagnosis can be made by a sleep study and specialist evaluation is recommended.
358
**Sleep Disorders** "*(RBD)*" Mx
- reassurance - improving sleep practices - interventions as necessary to address safety issues - If more **severe**, and if there is concern about physical injury occurring ->>> **low-dose clonazepam**.
359
**Sleep Disorders** "*Narcolepsy*" features
- appear between adolescence and the age of 30 years - chronic daytime sleepiness + "**CHAP**"  C - **Cataplexy** - **specific sign** (sudden loss of muscle tone during wakefulness, associated with or without strong emotion)  H - **Hallucinations** (often visual) on falling asleep (hypnagogic) or waking (hypnopompic)  A - **Attacks** (sudden unpredictable episodes of sleep; it can last secs to mins) - **most common sign**  P - Sleep **Paralysis** muscle paralysis on falling asleep or waking ## Footnote all symptoms need not to be present
360
**Sleep Disorders** "*Narcolepsy*" Dx
- clinical history - absence of other sleep disorders (particularly OSA) on overnight sleep study - objective evidence of excessive daytime sleepiness (using a multiple sleep latency test or maintenance of wakefulness test)
361
**Sleep Disorders** "*Narcolepsy*" Mx
* **Non-pharmacologic** -- Scheduled naps can help, but seldom suffice as primary therapy -- Advise the patient to follow good sleep practices. -- Advise patients with severe sleepiness to avoid dangerous activities at home and at work. They should not operate a motor vehicle until sleepiness is adequately managed and they satisfy the Australian standards of fitness to drive * **Pharmacologic** -- Modafinil (first-line drug therapy for reducing daytime sleepness and sleep attacks) OR -- dexamphetamine and methylphenidate. If Cataplexy, sleep paralysis and hallucinations -- TCAs or SSRI can be added -- GHB is also effective (not mentioned by the ATG)
362
**Sleep Disorders** "*Obstructive Sleep Apnoea*" Predictive Factors/Symptoms
"**SAD BBANG TF**"  S - **Snoring**  A - **Apnoea** (observed by someone else)  D - **Daytime** sleepness/irritability/ poor attention  B - **BP** (HIGH)  B - **BMI** (HIGH)  A - **Age** (OLDER)  N - **Neck** Circumference (LARGE)  G - **Gender** (MALE)  T - **Thyroid** disease  F - **Family History**
363
**Sleep Disorders** "*Obstructive Sleep Apnoea*" Dx
- overnight in-laboratory polysomnogram (**standard**) - Simplified home-based assessments may be appropriate in some settings as a screening tool for patients with **high pre-test probability of obstructive sleep apnoea (eg sleepy obese patients who snore and take antihypertensive drugs)** -- Home-based tests can be useful to rule in OSA in these patients, but not to rule out OSA (the tests have high specificity and low sensitivity) - patients who require urgent assessment are those with: -- unstable cardiovascular status (eg nocturnal angina or recurring cardiogenic pulmonary oedema) -- hypercapnic respiratory failure -- high pre-test probability of OSA who are about to undergo major surgery -- history of significant drowsiness while driving. A polysomnogram calculates the number and severity of obstructive apnoeas and hypopnoeas with desaturation and arousal.
364
**Sleep Disorders** "*OSA*" Polysomnopraphy Results
* **Minimal OSA** -- is indicated by an apnoea–hypopnoea index of LESS than 5 events per hour * **Significant OSA** -- is indicated by an apnoea–hypopnoea index of MORE than 5 events per hour * **Severe OSA** -- more than 30 events per hour.
365
**Sleep Disorders** "*OSA*" Treatment
* Mild disease WITHOUT intercurrent HAS or CVD and NO DAYTIME DYSFUNCTION -- General Measures — Weight reduction — Avoidance of alcohol and drugs that affect sleep — Positional therapy (supine --> lateral position) — Reduced nasal resistance (with smoking cessation and using intranasal corticosteroid spray) * CPAP + General Measures * Mandibular advancement splints + General Measures (effective only in mild to moderate OSA)
366
**Sleep Disorders** "*OSA*" CPAP INDICATIONS
* severe OSA (apnoea–hypopnoea index > 30) * mild to moderate OSA with symptoms of daytime dysfunction * mild to moderate OSA with HAS or other CVD.
367
**Sleep Disorders** "*Restless legs syndrome (RLS)*" Sx
"**URGE**"  U - **Urge** to move  R - **Rest** worsens  G - **Gets better** with activity  E - **Evening** is worse
368
**Sleep Disorders** "*Restless legs syndrome (RLS)*" Sx
- limb discomfort at rest, followed by an **urge to move the affected part** -- Symptoms affect both arms and legs in about 50% -- symptoms confined to the arms are uncommon -- can be bilateral (more common) and unilateral - may describe the sensation as creeping, crawling, itching, burning, searing, tugging, pulling, drawing, aching, hot and cold, electric current–like, restless or painful. - Usually, symptoms occur when the patient has been **lying quietly**, and last for a few minutes or an hour - can also occur when the patient is sitting quietly, but this is rare - When the patient is more **mentally rested and physically quiet, the symptoms are more intense** - The syndrome is **worse from the evening** to the early hours of the morning, whether or not the patient is asleep.
369
**Sleep Disorders** "*Restless legs syndrome (RLS)*" Dx
- **clinical criteria (a sleep study is not usually needed)** - can be idiopathic or secondary (more common)
370
**Sleep Disorders** "*Restless legs syndrome (RLS)*"common causes
— iron deficiency (most common cause seen in 20%) — DM — pregnancy — end-stage kidney disease (ESKD) — Some drugs (eg antidepressants, antihistamines) can exacerbate the condition.
371
**Sleep Disorders** "*Restless legs syndrome (RLS)*"Mx
- Most cases are mild and don't need treatment - Mild, infrequent symptoms --->>> lifestyle changes: -- physical exercise -- good sleep practices - Exclude iron deficiency -- Replace iron so the serum ferritin > 50 micrograms/L.
372
**Sleep Disorders** "*Restless legs syndrome (RLS)*" Pharmacologic Mx
- Mild, infrequent (if LSC not sufficient) -- Levodopa PO - More severe symptoms -- Pramipexole PO (dopamine agonist) OR -- Gabapentine PO OR -- Pregabalin PO
373
**Berievement & Grief** (Normal) 1st Stage, timframe, features
**DENIAL** From event to hours to several days -- disbelief -- emotional numbness ## Footnote Anxiolytics or hypnotics may be helpful for a brief period in acute grief to control excessive anxiety or assist with sleep for a few nights (usually for fewer than 7 nights), but there is a risk that ‘brief’ use can become long-term
374
**Berievement & Grief** (normal) 2nd Stage, timframe, features
**Grief and despair** few weeks to 6 months -- separation distress—preoccupation with thoughts or images of the deceased, especially yearning for the deceased -- intense sadness, tearfulness, guilt, blame -- loss of usual levels of activity and capacity to undertake normal tasks -- withdrawal from others --physical symptoms, including fatigue and loss of appetite -- sleep disturbance, restlessness -- fleeting images (illusions, even hallucinations) about the deceased -- anxiety (about the future) -- anniversary reaction (resurgence of acute grief triggered by the anniversary of the death)
375
**Berievement & Grief** (normal) 3rd Stage, timframe, features
**ACCEPTANCE** After 6 months following the death (usually resolves within 12 months) - Only memories of good times left.
376
**Berievement & Grief** (normal) Mx
- Supportive psychotherapy and counselling. - Short acting sleeping agents, if severe problem with sleep
377
**Berievement & Grief** (Abnormal/complicated) Features
Symptoms of stage 2 that: -- persist more than 6 months after the death -- impact on day-to-day functioning Clinical features of complicated grief include: - Persistent, intense yearning, longing, and sadness. - maladaptive thoughts and behaviours related to the death or the deceased - Rumination is common and is often focused on angry or guilty recrimination related to circumstances of the death. - continuous emotional dysregulation about the death - social isolation - Hallucinations - suicidal ideation.
378
**Berievement & Grief** (Abnormal/complicated) Risk Factors
-History of mood or anxiety disorders. -History of alcohol or drug abuse. -Multiple losses -History of depression -Development of depression early in bereavement -there are concurrent losses and other significant stresses -the relationship with the deceased was ambivalent, conflicted or overly interdependent -family/friends are unsupportive or in conflict.
379
**Berievement & Grief** (Abnormal/complicated) Mx
 Psychiatrist referral  CBT and counselling (First-Line)  SSRI/ Antipsychotics.  ECT
380
**ECT** Indications
* severe depression -- if features of severe depression are present; -- if ECT is the preferred method of treatment in a voluntary patient with severe depression -- If previous good response to ECT in patients with severe depression * treatment-resistant mania * treatment-resistant bipolar depression * treatment-resistant acute schizophrenia * schizoaffective psychoses in the acute phase
381
**ECT** Features of severe depression that meet criteria for ECT
* psychotic depression (**ECT is more effective than antidepressants combined with antipsychotics**) * melancholic depression unresponsive to antidepressants * depressive stupor, severe psychomotor retardation (catatonia) leading to severe self-neglect, or life-threatening anorexia * severe postnatal depression and psychosis * strong suicidal ideation ## Footnote **ECT** is **superior** to any other therapy (ie CBT an/or Antidepressants) in the treatment of **Severe Depression**
382
**ECT** Overall response rate
60-90%
383
**ECT** Contra-indication
Raised Intracranial pressure (ICP) - ONLY ABSOLUTE CONTRAINDICATION  SITUATIONS OF HIGH RISK: (warrants specialist review) - Hypertension - Myocardial Infarction <3 m - Bradyarrythmias - Cardiac Pacemakers - Intracranial Pathology (Aneurysms, Epilepsy) - Skull Defect - Retinal Detachment - Osteoporosis
384
**ECT** Legislation
Mental Health Act in Australia * Patient is able to give **CONSENT** -- at least two authorized medical practitioners, **one of them must be a psychiatrist**, should agree that ECT is indicated and right treatment option. -- The same rule aplies even if a voluntary patient presents for ECT -- If medical practitioner is concerned about the capacity of the patient to decide, an application to **Mental Health Review Tribuna**l should be made * Patient is **INCOMPETENT** which precludes their ability to consent or refuse treatment -- must be **detained involuntarily** in hospital and kept safe with 24 hour constant nursing supervision and given supportive care while application to a Mental Health Review Tribunal (or equivalent independent statutory authority) is made -- **Relatives must be informed** of the treatment plan -- **Relatives are not legally able to consent or refuse on patients behalf** even under enduring power of attorney
385
**ECT** Adverse effects
Most common adverse effects - muscle aches and pains (from the muscle relaxant) - headaches and transient confusion for ~ 1 hour after treatment. other adverse effects include - reversible short-term retrograde memory loss (particularly of autobiographical memories (memories of personal experiences), for the period of treatment and to a lesser degree for antecedent events. - in generall, new learning appears unaffected after ECT and is often improved after recovery from depression. - Cognitive adverse effects are greater with bilateral than right unilateral treatment. - Some patients with post-ECT confusion have ongoing ictal activity (non-convulsive status epilepticus) than can be shown on EEG monitoring, and it can be stopped with agents like **midazolam** - **There is NO CONTINUED memory impairment once treatment is completed** - **DEMENTIA IS NOT LISTED AS AN ADVERSE EFFECT**
386
**ECT** and psychotropic drugs
**Where possible, it is usually desirable to cease psychotropic drugs ** * **Benzodiazepines** should be tapered and **ceased** --- they raise the seizure threshold and may impair the efficacy of ECT * taper and **discontinue** all **antidepressants** -- There is little to be gained from continuing failed antidepressants during acute ECT and there is some evidence it may increase adverse effects. * **Lithium** should be **ceased** -- Although Lithium does not impair the effectiveness of ECT, it may occasionally result in severe postictal confusion even at a low serum concentration * **Antiepileptics** -- In patients with **epilepsy**, **not usually withdrawn** (high risk of spontaneous seizures) -- In patients taking antiepileptics for the management of **bipolar disorder**, are **preferably withdrawn** (before or early in the course of ECT). They can be quickly reinstated at the conclusion of the course of therapy if necessary, with the exception of lamotrigine, which requires the usual slow dose titration to reduce the risk of skin rash. * **Antipsychotics** -- may be continued unless clearly ineffective or interacting adversely with ECT (eg prolonged seizures with clozapine) * **Non-benzodiazepine hypnotics** (eg. Zolpidem, Zopiclone) can be used if needed (eg. procedure-related anxiety)
387
**CBT** principals
- cognitions may control feelings and behaviour ↓ - behaviours affect thought patterns and emotions
388
**CBT** useful in..
– Psychosis. – Depression. – Anxiety – Phobias (Exposiure Therapy) – Personality diosrder.(DBT in BPD) – Eating disorders – Insomnias (but not Parasomnias) – Grief
389
**SUICIDE** Risk Assessment
 **S** - **SEX MALE** **(1)**  **A** - **AGE** < 20 & > 45 **(1)**  **D** - **DEPRESSION** **(2)**  **P** - **PYSCHIATRIC HX** **(1)** (PREVIOUS ATTEMPTS)  **E** - **EXCESSIVE DRUG USE** **(1)**  **R** - **RATIONALITY LOSS** **(2)** (PYCHOSIS or SEVERE DEPRESSION)  **S** - **SEPARATED** **(1)**  **O** - **ORGANIZED PLAN** **(2)**  **N** - **NO SUPPORT** **(1)**  **S** - **SICKNESS** **(1)**
390
**SUICIDE** When is the period at which patient with a mental health disorder is at their highest risk of suicide?
On discharge from the hospital ## Footnote - The risk of suicide in the 4 weeks after psychiatric inpatient care is around 100 times greater than that for the general population. - This risk declines rapidly over subsequent weeks. - The strongest risk factor for self-harm after discharge is an admission for self-harm in the previous 12 months.
391
**SUICIDE** How soon after discharge should patient who attempted suicide be followed up?
1 WEEK
392
**SUICIDE** 2 questions that MUST be asked to assess suicidal ideation
1. Do you feel hopeless? 2. Have you felt that you've lost interest in your usual activities?
393
**Defence Mechanisms** Imature (types) | https://pmc.ncbi.nlm.nih.gov/articles/PMC8555762/ ## Footnote hierarchically ordered
- **Acting out** (externalisation of regression, thus imature) -- **Acting in** (internalisation of anxiety) - **Passive aggression** (demonstrating hostile feelings in a nonconfrontational manner) - **Regression** (reversion to an earlier stage of development) **------------------------------------------------------------------------------** - **Sppliting** (an individual is unable to integrate mixed feelings (eg, seeing others as alternately "all bad" and "all good") **------------------------------------------------------------------------------** - **denial** (refuse to recognise or acknowledge a threatening situation) -- **compensation** or **counter dependency** (respond to limits being recommended on one's behaviour by taking on even more work/responsibilities. - a renunciation is adopted to evade anxiety out of one's impulses) - **Projection**(disguising one's own unacceptable impulses/thuoghts/feelings/motives by **attributing** to another person. Eg, one is angry but say the other person is angry) - **Rationalisation** (attempting to justify or excuse a behavior or decision rather than acknowledging the true motives, significance, or consequences of it- The subject avoids feelings of guilt or shame) **------------------------------------------------------------------------------** - **Neurotic** (displacement, Dissociation, reaction formation, regression, intellectualisation)
394
**Defence Mechanisms** Neurotic
- **displacement** (**redirection** of emotions or impulses onto a neutral person or object unrelated with the episode) - **reaction formation** (transforming an unacceptable feeling or impulse into its extreme **opposite** - **it does not provide satisfaction**) - **Intellectualisation** (transformation of a distressing event into a situation devoid of emotion to avoid confrontation of uncomfortable emotional components)
395
**Defence Mechanisms** Mature defensive category (no impairment of insight)
"**SASH**" - S - **SUBLIMATION** (person channels unacceptable thoughts or impulses into **socially acceptable behavior**, which is similar to the original thoughtlimpulse and **provides satisfaction**) - A - **ALTRUISM** (alleviating nrgative feelings via unsolicited generodity, through unselfish devotion, or service to others - which provides **gratification**) - S - **SUPRESSION** (intentionally withholding an idea/feeling from conscious awareness but only **temporarily** (vs repression which is permanently) and **no changes in personality** (vs dissociation which is accompanied by drastic changes) - H - **HUMOR** (Lightheartedly expresing uncomfortable feelings to shift the internal focus away from the distress)
396
which are the** five stages **of human development according to **Freud's theory of psychosexual development**
 **O** - **Oral** **first stage**, which takes place from **birth-one year old**  **A** - **Anal** **second stage**, which takes place from **1-3 years old**  **P** - **Phallic** **third stage**, which takes place from **3-6 years old**  **L** - **Latency** **fourth stage**, which takes place from **6-12 years old**  **G** - **Genital** **fifth stage**, which takes place from **13-18 years old**
397
Erikson's Stages of Psychosocial Development ## Footnote https://www.ncbi.nlm.nih.gov/books/NBK556096/
1 Trust vs. Mistrust (0-18 months): Developing trust through consistent caregiving 2 Autonomy vs. Shame (18 months-3 years): Learning independence and self-control 3 Initiative vs. Guilt (3-5 years): Exploring and taking action in the world 4 Industry vs. Inferiority (5-12 years): Developing competence through achievements 5 Identity vs. Role Confusion (12-18 years): Forming personal identity and life direction 6 Intimacy vs. Isolation (18-40 years): Building meaningful relationships 7 Generativity vs. Stagnation (40-65 years): Contributing to society and future generations 8 Integrity vs. Despair (65+ years): Reflecting on life and finding meaning
398
**SEXUAL DYSFUNCTION** "*PREMATURE EJACULATION*"
Choice of treatment depends on the couple's preference. - **Topical preparations** -- (lidocaine+prilocaine) 10 to 20 minutes before intercourse. - **SSRIs** -- *single dose before sexual activity* (less likely to be associated with adverse effects (eg anorexia, reduced libido and/or anejaculation) >>> DAPOXETINE VO OR >>> PAROXETINE VO OR >>> SERTRALINE VO -- *continuous/daily dosing* >>> PAROXETINE VO OR >>> SERTRALINE VO ## Footnote NOTE: - Relaxation - squeeze method - sex therapy with partner **HAVE DUBIOUS LONGTERM BENEFIT**
399
Other personality disorders
Personality Change: - Labile type - Masochistic - Disinhibited type - Aggressive type - Passive Aggressive type - Apathetic type - Combined type - Unspecified type
400
Pyromania is a one of _______ disorder
Several impulse control disorders
401
Diagnosis of chronic insomnia
1. A self-reported complaint of poor sleep quality 2. Sleep difficulties occur despite adequate sleep opportunity. Impaired sleep produces deficits in daytime function. 4. Sleep difficulty occurs **three nights per week** and is present **for three months**
402
How much time should infants exposed to SSRI's be observed for
3 days (monitoring for serotonin syndrome)
403
Difference between Adjustment Disorder & Regular Grief
Grief usually occurs after loss of something like any close relative or property, however, there are l**ess behavioural symptoms **and it is a self-limiting condition
404
Perception - definition?
one's ability to accurately take in information about the world. Most common: - illusions - Hallucinations
405
Risk Factors for suicide?
- Guns - Recent suicide attempts - Ongoing thoughts of suicide - Self-harm - Ethanol - Substances mnemonic "Guns & ROSES"
406
Healthy BMI
20=25
407
Underweight BMI
18
408
Overweight BMI
25-29
409
Obese BMI
30-39
410
Morbidly obese BMI
< 40
411
**PREGNANCY** '*Antidepressants*' Which should be avoided?
- Paroxetine - Fluoxetine ## Footnote Concern about harm–benefit analysis for their use in the perinatal period is commonly encounteredconcern about harm–benefit analysis for their use in the perinatal period is commonly encountered however, there is no evidence to recommend any particular SSRI over another during pregnancy. There are six areas of concern: terato-genicity, spontaneous abortion and premature labour, low birth weight/small-for-gestational age, poor neonatal adaptation, persistent pulmonary hypertension of the newborn, and neurodevelopmental difficulties in older children. There were limitations and inconsistencies in published findings, and the overall consensus is that concern about teratogenicity should not deter prescription of SSRIs during pregnancy for treatment of moderate-to-severe major depression and anxiety disorders - **Paroxetine** is linked to reports of increased risk of **cardiovascular malformations**. As the **absolute risk is low**, women who find themselves unexpectedly pregnant should not be advised to abruptly stop the drug. - **Fluoxetine** (due to its longer half-life)
412
**PREGNANCY** '*Antipsychotics*' which one should be avoided and reason
**OLANZAPINE** increased risk of maternal gestational diabetes ## Footnote There is not sufficient evidence to recommend any one antipsychotic over another during pregnancy. Drug choice should be made with consideration of previous effective treatment and patient preference. During pregnancy, switching from one antipsychotic to another puts the patient at risk of relapse and of potential adverse effects to the fetus from exposure to multiple drugs. There are extensive data available about the safety of haloperidol used as an antipsychotic. However, first-generation antipsychotics may lead to extrapyramidal symptoms in the neonate Anticholinergic drugs should be avoided if possible during pregnancy.
413
**PREGNANCY** '*Bipolar Disorder*' Mx in PLANNED PREGNANCY in MILD disorder
- Slow withdrawal of Lithium (3-4 weks) before conception (if stable, and not severe symptoms) - If relapse of symptoms: -- Antipsychotics OR -- Lithium can be reinstated ~ 50 days of conception (**after cardiogenesis**) OR -- ECT
414
**PREGNANCY** '*Bipolar Disorder*' Mx in PLANNED PREGNANCY in SEVERE disorder
- continue with Lithium - consider ECT ## Footnote The benefits of lithium prophylaxis during pregnancy, in cases of severe bipolar disorder, may outweigh the risks, and lithium has been considered as a first-line treatment during pregnancy for some such women. For patients who are currently treated with valproate or carbamazepine, it is suggest switching treatment avoid the teratogenic effects of these two antiepileptics. The absolute risk of teratogenesis is much less with lithium than that found with valproate, carbamazepine and lamotrigine. According to Royal Australian and New Zealand College of Psychiatrists guidelines, if the use of a mood stabiliser is essential, lithium is the safest option as compared to other treatment options.
415
**PREGNANCY** '*Bipolar Disorder*' Mx in UNPLANNED PREGNANCY
- Continue treatment - investigate for any anomaly
416
**PREGNANCY** '*Mood Stabiliser*' Risk associated with the use of Lithium and the stage of pregnancy
Ebstein's anomaly - Lithium use during the first trimester of pregnancy ## Footnote Tricuspid valve are displaced downwards towards the apex of the right ventricle of the heart.
417
**PREGNANCY** '*Mood Stabiliser*' Risk of developing Ebstein's anomaly on patients on lithium?
approximately 1 in 1000 to 2000 compared with 1 in 20000 in the general population.
418
**PREGNANCY** '*Mood Stabiliser*' What investigation should done in any patient exposed to Lithium during pregnancy?
- High-resolution US at around 18-20 weeks Refer to Ebstein Centre if any anomaly is detected
419
**PREGNANCY** '*Mood Stabiliser*' Mx of Lithium at delivery?
- 24 to 48 hours before delivery (if the delivery is planned) - withheld at the onset of labour (if delivery is not planned) - Restart lithium at the prepregnancy dose after delivery ## Footnote To avoid floppy baby syndrome due to neonatal toxicity
420
**PREGNANCY** '*Anxiety disorders*' Mx
For anxiety and insomnia, the first-line treatment should be nonpharmacological.
421
**PREGNANCY** '*Anxiety disorders*' Risks associated to exposure to BZ drug in the 1st Trimester
* First trimester exposure to benzodiazepines is associated with increased **risk of cleft lip and/or palate**. ## Footnote * The first 8 weeks of pregnancy is the period of highest risk. A high-resolution US examination at 18 to 20 weeks.
422
**PREGNANCY** '*Anxiety disorders*' Risks associated to exposure to BZ drug in the 3rd Trimester
If benzodiazepines taken in late pregnancy, they can cause - neonatal drowsiness - respiratory depression - poor temperature regulation - poor feeding - hypotonicity (the ‘floppy infant syndrome’). - Neonatal withdrawal symptoms can present
423
**PREGNANCY** Psychiatric Syndromes that occur following childbirth
- postpartum blues: ~ 5 days after delivery - postpartum depression: within weeks/months after delivery - postpartum psychosis: within 2-4 weeks after delivery
424
**PREGNANCY** Nicotine dependece Mx
* **First-line:** CBT + counselling * NRT can be added if CBT not effective ## Footnote The available evidence suggests that, for pregnant women, counselling may exert more influence on smoking than pharmacological interventions. Nicotine replacement therapy (NRT) during pregnancy is controversial, as nicotine itself has been linked to some in-utero problems (excluding growth restriction but including neurotoxicity) in animal studies. However, there is an emerging consensus that with NRT the level of nicotine exposure to the fetus is less than that in women who continue to smoke heavily. Moreover, cigarette smoke is known to contain a large number of other potentially harmful ingredients, which are avoided in successful NRT. Unfortunately the randomised controlled trials to date have not clearly established the efficacy or safety of NRT during pregnancy, largely due to the low adherence to therapy. NRT can be used as an adjunct to counselling, especially in women smoking more than 10 cigarettes per day. However, it is usually not started unless a trial of psychological interventions has failed.
425
**'*Breastfeeding*'** *Postpartum* Blues Features & Rx
- **peak** within **4-5 days** - generally **time-limited** - spontaneously **remit with 10-14 days** - if symptoms last for more than 2 weeks, postpartum depression should be considered ## Footnote - Occurs in 80% of mothers following delivery (considered normal)
426
**'*Breastfeeding*'** Postpartum Depression clinical features
- **peak** at **12 weeks** - occurs between 6-12 months after the delivery, Sx: - marked mood swings - irritability towards the family - guilty thoughts about being a bad mother, - excessive anxiety about the wellbeing of the baby - irritability towards the family - agitation - poor memory and concentration - depressed mood and weight loss ## Footnote - prevalence 10-15%
427
**'*Breastfeeding*'** *Postpartum Depression * Mild-to-Moderate Rx
CBT
428
**'*Breastfeeding*'** *Postpartum Depression* Severe Rx
SSRI (Sertraline || Paroxetine) ## Footnote From published data, **sertraline and paroxetine** appear to have the **lowest transmission** into breastmilk and **fluoxetine, escitalopram and citalopram the highest**. Venlafaxine gives a higher mean relative infant dose than the SSRIs; however, for some women venlafaxine may have been prescribed during pregnancy or earlier due to lack of efficacy of other antidepressants. For these women, if they have a full-term infant who is otherwise well, breast-feeding should be encouraged.
429
**'*Breastfeeding*'** *Postpartum Depression* which SSRIs should be avoided ## Footnote Due to the risk of excretion into breastmilk
- Fluoxetine (due to its longer half-life) - Citalopram - Escitalopram ## Footnote - Fluoxetine, escitalopram and citalopram have the highest transmission into breastmilk - Fluoxetine has the potential to accumulate in the breastfed infant, and been associated with low weight gain, irritability, difficulty settling and infant gastrointestinal dysfunction.
430
**'*Breastfeeding*'** *Postpartum Psychosis * Risk Factors
- previous episode of postpartum psychosis - **history of bipolar disorder** (highest risk). - **maternal suicide** (20%) = rule out by psych eval first (notify child services & consult psychiatrist) - child harm & Infanticide (4%) ## Footnote Postpartum psychosis is rare (1 to 2 cases per 1000 live births);
431
**'*Breastfeeding*'** *Postpartum Psychosis * clinical features
- postpartum psychosis: within** 2-4 weeks** after delivery  Symptoms include: - agitation - elation (if an episode of bipolar disorder) - confusion - thought disorganisation - sleep disturbance - psychosis (hallucinations and delusions) - affective symptoms.
432
**'*Breastfeeding*'** *Postpartum Psychosis * Management
 The presentation is acute and usually requires inpatient management. Treatment in ACUTE MANIA – PSYCHOTIC EPISODE is: - antipsychotics and/or ECT, (for quick resolution)  depending on the underlying Dx – antipsychotics + Lithium/antiepileptics may be added or antidepressants.  If (+) hx of previous episode of postpartum psychosis = PROPHYLACTIC USE LITHIUM after delivery reduces the likelihood of a recurrence.
433
**'*Breastfeeding*'** Safe Anti-psychotic ## Footnote Overall safe drug in case of FIRST Mania/Psychosis episode
Haloperidol ## Footnote - In lower dose, ie less than 10 mg haloperidol daily or equivalent, they are usually regarded as safe
434
**'*Breastfeeding*'** Anti-psychotics to avoid
- Olanzapine - Clozapine ## Footnote - Additional studies are required to definitively establish safety, and the association of **OLANZPINE** with some reversible adverse effects (jaundice, impaired weight gain, sedation, irritability and tremor) in a small series of breastfed babies has led the manufacturer to recommend **against breastfeeding while taking olanzapine**. - **CLOZAPINE** should not be used while breastfeeding (due to high concentration in breastmilk and the theoretical risk of agranulo-cytosis occurring in the infant). - The first-generation antipsychotics, especially at high dose, have occasionally been associated with adverse reactions in breastfed infants (eg urinary retention, dystonic reactions).
435
**'*Breastfeeding*'** what is the recommendation while breastfeeding if taking Olanzapine
- **continuation** of clozapine for maternal wellbeing PLUS - the **use of formula feeding** rather than breastfeeding.